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Abstract 
Introduction: Cancer is an emerging health problem in South Africa, with breast cancer 
being one of the leading cancers affecting women globally. Therefore, there is a need to find 
novel targets to improve the therapeutic options for these patients. A recently proposed 
target is the mitogen-activated protein kinase phosphatase-1 (MKP-1). Studies have 
suggested that mitogen-activated protein kinase phosphatases are involved in the 
development of cancer and play an important role in the response of cancer cells to 
chemotherapy. Additionally, numerous studies have indicated that there is increased 
expression of MKP-1 in breast cancers where its over-expression is proposed to be a 
significant mediator in chemo-resistance. We propose that inhibition of MKP-1 will increase 
the cytotoxic effect of doxorubicin in breast cancer cells, thus making the cells more 
responsive to treatment leading to increased cell death through autophagy and apoptosis. 
Methods: In MDA-MB231 cells, MKP-1 was inhibited using sanguinarine or MKP-1 siRNA and 
this was compared to a known inducer of MKP-1, dexamethasone. MDA-MB231 cells were 
treated with doxorubicin alone or in combination with MKP-1 inhibitors or an inducer. 
Following treatment, cell death was determined by trypan blue and a caspase glo assay as 
well as with western blotting. Autophagy was determined by western blotting and flow 
cytometry. LC3 and p62 were used as markers of autophagy and caspase 3 and PARP as 
apoptosis markers. Likewise, the level of MKP-1 expression under conditions of MKP-1 
induction, inhibition or silencing was evaluated by means of western blotting. C57BL6 
tumour bearing mice was used to analyse apoptosis and autophagy in vivo under conditions 
of MKP-1 inhibition, using sanguinarine, together with doxorubicin treatment. Western 
blotting was used to determine levels of caspase 3, LC3, p62 and MKP-1 expression. 
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Results and discussion: A concentration and time curve indicated that 5 µM doxorubicin 
reduced cell viability in the MDA-MB231 cells significantly after 24 hours of treatment. MKP-
1 expression was significantly reduced with sanguinarine and MKP-1 siRNA. Furthermore, 
our results indicate a significant increase in apoptosis in MDA-MB231 cells when treated 
with doxorubicin, under conditions of MKP-1 inhibition or MKP-1 silencing. Also, an increase 
in autophagic activity was observed following treatment with doxorubicin in combination 
with sanguinarine. Whole excised tumours of C57BL6 mice also showed an increase in 
apoptosis and autophagy following treatment with sanguinarine in combination with 
doxorubicin. This indicates that the inhibition of MKP-1 with sanguinarine sensitized the 
MDA-MB231 cells and E0771 cell tumours to doxorubicin-induced-apoptosis through a 
mechanism involving autophagy.  
Conclusion: This is an encouraging finding that could hopefully be used in future studies to 
overcome doxorubicin-resistance in breast cancer cells overexpressing MKP-1. Targeting 
MKP-1 can have potential therapeutic benefits for breast cancer patients by making 
chemotherapy more effective. Sanguinarine thus has potential to be developed as a clinically 
relevant inhibitor of MKP-1 which could provide a novel avenue for therapeutic intervention 
in combination with chemotherapy in breast cancer patients. 
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Opsomming 
Inleiding: Kanker is 'n vinnig groeiende gesondheidsprobleem in Suid-Afrika, met borskanker 
as een van die vernaamste kankers wat vroue wêreldwyd raak. Daar is dus 'n behoefte aan 
nuwe terapeutiese opsies vir hierdie pasiënte en mitogeen-geaktiveerde proteïenkinase 
fosfatase-1 (MKP-1) is onlangs voorgestel as ‘n moontlike teiken. Verskeie studies toon dat 
mitogeen-geaktiveerde proteïenkinase fosfatases betrokke is by die ontwikkeling van kanker 
en ook belangrike rolspelers is in die reaksie van kanker op chemoterapie. Daarbenewens 
toon talle studies dat daar verhoogde MKP-1 uitdrukking in borskanker is, asook dat dit ‘n 
belangrike bemiddelaar is vir die weerstand wat borskanker teen chemoterapie bied. Ons 
het dus voorgestel dat die inhibisie van MKP-1 die sitotoksiese effek van doxorubicin op 
borskanker selle sal verhoog; sodoende sal die kanker selle beter reageer op behandeling en 
dit sal dus lei tot verhoogde seldood deur autofagie en apoptose. 
Metodes: MKP-1 is geïnhibeer met behulp van sanguinarine of MKP-1 siRNA in MDA-MB231 
selle en dit is vergelyk met 'n bekende MKP-1 induseerder, dexamethasone. MDA-MB231 
selle is met doxorubicin alleen behandel of in kombinasie met MKP-1 inhibeerders of ‘n 
induseerder. Seldood is bepaal deur middel van ‘n trypan blou en kaspase toetsingsmetode, 
asook met die westelike kladtegniek. Autofagie is bepaal deur westelike kladtegniek en 
vloeisitometrie. LC3 en p62 is gebruik as merkers van autofagie en kaspase 3 en PARP is as 
apoptose merkers gebruik. MKP-1 uitdrukking is geëvalueer deur middel van westelike 
kladtegniek. C57BL6 muise met kankeragtige gewasse is gebruik om apoptose en autofagie 
in vivo te ondersoek. MKP-1 is geïnhibeer met sanguinarine en die muise is behandel met ‘n 
kombinasie van sanguinarine en doxorubicin. Kaspase 3, LC3, p62 en MKP-1 uitdrukking is 
bepaal deur middel van die westelike kladtegniek. 
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Resultate en bespreking: ‘n Konsentrasie en tyd kurwe het aangedui dat 5 μM doxorubicin 
die MDA-MB231 selle se lewensvatbaarheid aansienlik verminder het na 24 uur. MKP-1 
uitdrukking is ook aansienlik verminder met sanguinarine en MKP-1 siRNA. Verder dui die 
resultate op 'n beduidende toename in apoptose in MDA-MB231 selle na behandeling met 
doxorubicin onder toestande van MKP-1 inhibisie. 'n Toename in autofagiese aktiwiteit is 
waargeneem na behandeling met doxorubicin en sanguinarine. Die kankeragtige gewasse 
van die C57BL6 muise toon ook 'n toename in apoptose en autofagie na behandeling met 
sanguinarine en doxorubicin. Hierdie resultate dui daarop dat die inhibisie van MKP-1 met 
sanguinarine die MDA-MB231 selle en E0771 sel gewasse gesensitiseer het tot doxorubicin-
geïnduseerde apoptose deur middel van ‘n meganisme wat autofagie insluit.  
Gevolgtrekking: Hierdie bevinding kan hopelik in toekomstige studies gebruik word om 
doxorubicin weerstand te oorkom in borskanker selle waar MKP-1 verhoog is. Deur MKP-1 te 
teiken, kan dit lei tot potensiële terapeutiese voordele vir borskanker pasiënte en sodoende 
kan dit chemoterapie meer effektief maak. Sanguinarine het dus die potensiaal om 
ontwikkel te word as ‘n klinies relevante inhibeerder van MKP-1 wat sodoende kan dien as 
terapeutiese intervensie in kombinasie met chemoterapie vir borskanker pasiënte. 
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Chapter 1:  
Introduction 
1.1 Motivation for study 
Cancer is an emerging health problem in South Africa, with breast cancer being one of the 
leading causes of death in women globally (Vorobiof et al. 2001). Although major progress 
has been made in reducing mortality rates due to increased screening, digital 
mammography, specialized care and widespread use of therapeutic agents, defining the 
genetic architecture of breast cancer still remains an important long-term goal for the 
development of more effective therapeutic strategies and early interventions (Hicks et al. 
2011). 
Furthermore, cancer cells are becoming increasingly more resistant to conventional 
chemotherapeutic agents; therefore there is a need to find novel targets to improve the 
therapeutic options for these patients. A recently proposed target is the mitogen-activated 
protein kinase phosphatase-1 (MKP-1). It was shown in a recent study that MKPs are 
involved in the development of cancer and play an important role in the response of cancer 
cells to chemotherapy (Wu. 2007). In human breast cancer, MKP-1 was found to be 
increased in malignant samples compared to non-malignant samples (Wu. 2007). This might 
implicate MKP-1 as a critical role player in cancer development and may be a useful marker 
for predicting the survival of patients with cancer. Additionally, it has been indicated that 
there is increased expression of MKP-1 in ovarian, breast and prostate cancer (Rojo et al. 
2009). Here, overexpression of MKP-1 is proposed to be a significant mediator of 
chemoresistance in these cancers.  
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It has been shown that MKP-1 inhibits events associated with apoptosis, including the 
activation of caspase-3 and proteolytic cleavage of the caspase-3 substrate, poly (ADP 
ribose) polymerase (PARP) (Franklin et al. 1998). These findings indicate the MKP-1 acts 
through upstream caspase activation within the apoptotic program (Franklin et al. 1998). 
Another mechanism which is used by cancer cells to induce chemoresistance is to increase 
autophagy induction. Under normal conditions, basal autophagy is responsible for protein 
turnover and the elimination of damaged or aged organelles and cytoplasmic components to 
maintain homeostasis in the cells (Maiuri et al. 2007). Autophagic induction under 
pathological conditions is considered as a pro-survival mechanism; however inappropriate 
activation of autophagy can also result in cell death (Yang et al. 2008).  
1.2 Problem statement 
A major goal in the search for an effective chemotherapeutic agent is to increase the 
susceptibility of cancer cells to cell death without harming normal cells. Doxorubicin is a 
well-known chemotherapeutic agent, with high anti-tumour efficacy, for the treatment of 
breast cancer patients. However, its clinical effects are limited due to its dose-dependent 
side effects such as cardiotoxicity (Roninson et al. 2001). Furthermore, resistance to 
doxorubicin therapy has also become a major problem in the treatment of this disease 
(Smith et al. 2006). 
1.3 Hypothesis 
We hypothesize that the inhibition of MKP-1, using a chemical inhibitor or siRNA, will 
increase the cytotoxic effect of doxorubicin (chemotherapeutic drug) in breast cancer cells, 
thus making the cells more responsive to treatment which will lead to increased cell death 
through autophagy and apoptosis. 
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1.4 General aims 
This study therefore aims to inhibit MKP-1 in breast cancer cells to sensitise it to doxorubicin 
treatment. This could eventually lead to the usage of lower doses of doxorubicin which will 
limit the harmful side-effects on normal cells and increase cell death to overcome resistance 
in cancer cells. 
1.5 Specific aims 
The aims of the research were: 
 First, to determine a dose for doxorubicin to induce apoptosis in breast cancer cells 
(MDA-MB231). 
 Secondly, to characterize the effect of doxorubicin treatment on apoptosis under 
conditions of MKP-1 induction and inhibition to determine the functional role of 
MKP-1 in apoptosis. 
 Thirdly, to determine the level of MKP-1 expression in breast cancer cells treated 
with a MKP-1 inducer (dexamethasone), MKP-1 inhibitors (sanguinarine or MKP-1 
siRNA) and doxorubicin. 
 Fourthly, to inhibit (sanguinarine, MKP-1 siRNA) and induce (dexamethasone) MKP-1 
to determine the role of MKP-1 in autophagy during doxorubicin treatment in breast 
cancer. 
 Fifthly, to determine whether inhibiting MKP-1, with siRNA or sanguinarine, will 
improve the cytotoxic effect of doxorubicin in breast cancer cells. 
 Finally, to determine the effect of MKP-1 inhibition, with sanguinarine, and combined 
doxorubicin treatment on autophagy and apoptosis in vivo in C57BL6 tumour bearing 
mice. 
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1.6 Structure of the thesis 
The effect of MKP-1 inhibition on the cytotoxicity of chemotherapeutic drugs in breast 
cancer is explored in this dissertation. Chapter 1 is an introductory chapter to present the 
background of the study as well as the aims and hypothesis. Chapter 2 reviews the current 
knowledge on MKP-1 expression in cancer and the effect that it has on autophagy and 
apoptosis. Chapter 3 highlights the methods used to collect data and Chapter 4 presents the 
results. Chapter 5 discuss the results in context with the data, and ends with conclusions and 
recommendations for future research. 
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Chapter 2:  
Literature review 
2.1 Introduction 
Cancer is a disease characterized by the unrestrained growth and spread of abnormal cells, 
which, if not ceased, can result in death (Garcia et al. 2007). It is caused, both by external 
factors (chemicals, radiation and infectious organisms) and internal factors (inherited 
mutations, hormones and mutations occurring from metabolism) that may act together or in 
sequence to promote carcinogenesis (Garcia et al. 2007). All cancers encompass errors in 
genes that control cell growth, division and death. Most of the genetic abnormalities that 
affect cancer risk are in fact not hereditary but result from gene mutations occurring 
throughout one’s lifetime.  
 
  
Figure 2.1: Incidence of Breast cancer compared to other cancers in women of all 
ages in South Africa (WHO, 2010). 
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Worldwide, public health data indicate that the burden of breast cancer in women, 
measured by incidence, mortality and economic costs, is extensive and on the increase 
(Jemal et al. 2011). Breast cancer is currently the most prevalent cancer and the primary 
cause of cancer related deaths in women worldwide, accounting for 23% (1.38 million) of 
total new cancer cases and 14% (458 400) of the total cancer deaths in 2008 (Jemal et al. 
2011).  
Worldwide, it is estimated that one million women are diagnosed every year and, of this one 
million, more than 410 000 will die from the disease (Coughlin and Ekwueme. 2009). In 
South Africa, breast cancer is now the most prevalent cancer in woman (Figure 2.1) 
(Vorobiof et al. 2001) and it is estimated that the incidence of breast cancer will increase 
with 15.8% by 2015 in this population (United Nations. 2008).  
The statistics are alarming, and finding practical solutions to help improve breast cancer 
treatment is imperative. Major progress has been made to reduce the mortality rates; these 
include increased screening, digital mammography, specialized care and widespread use of 
therapeutic agents. However, an important long-term goal for the development of more 
effective therapeutic strategies would be to define the genetic architecture of breast cancer 
(Hicks et al. 2011).  
In cancer, the normal mechanisms of cell cycle regulation are dysfunctional; oncogene and 
tumour-suppressor gene mutations drive the neoplastic process by increasing tumour cell 
number through over-proliferation of cells or inhibition of cell death or cell-cycle arrest (King 
and Cidlowski. 1998; Lowe et al. 2004; Vogelstein and Kinzler. 2004). These cells have 
complementary capabilities that enable tumour growth and metastasis. Hanahan and 
Weinberg (Hanahan and Weinberg. 2000) described these capabilities to be: self-sufficiency 
in growth signals, insensitivity towards anti-growth signals, the ability to evade apoptosis, 
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limitless replicative potential, sustained angiogenesis and the ability to invade other tissues 
and metastasize. More recently they added the ability to re-program energy metabolism and 
the ability to evade immune destruction to the already existing hallmarks of cancer 
(Hanahan and Weinberg. 2011). 
Since cancer develops through many pathophysiological mechanisms and several signalling 
pathways play a role in disease progression, exploiting certain mediators of these pathways 
can potentially be therapeutic.  
2.2 Mitogen-activated protein kinase signalling 
Mitogen-activated protein kinases (MAPKs) are major signal transduction molecules that 
play a vital role in the regulation of a variety of cellular responses, including cell 
proliferation, differentiation and apoptosis (Wu. 2007). Mammalian MAPKs mainly consist of 
three sub-families: The c-Jun NH2-terminal protein kinases (JNKs), the p38 MAP kinases, and 
the extracellular signal-regulated kinases (ERKs 1 & 2), can be activated by a variety of 
stimuli including growth factors and cellular/extracellular stresses (Wu. 2007).  
MAPKs are activated in response to stimuli through the reversible phosphorylation of both 
threonine and tyrosine residues in the catalytic domain by upstream dual-specificity kinases 
namely MKK (MAP kinase kinase) (Wu. 2007). The MKKs are, in turn, activated by MAPK 
kinase kinases (MKKK or MEKKK) (Chang and Karin. 2001; Kennedy and Davis. 2003; Pearson 
et al. 2001). Upon activation, MAPKs phosphorylate a number of substrates which 
subsequently activate signalling pathways leading to diverse outcomes such as cell 
proliferation and apoptosis (Chang and Karin. 2001). The dephosphorylation and subsequent 
inactivation of MAPKs by members of the mitogen-activated protein kinase (MAPK) 
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phosphate (MKP) family has been shown to play a critical role in negatively regulating MAPK 
signal transduction pathways (Wu. 2007). 
The MAPK phosphatases (MKPs) are a family of dual-specificity protein phosphatases that 
are responsible for the dephosphorylation of both phosphothreonine and phosphotyrosine 
residues in MAP kinases, including JNK, the p38 MAPK, ERK (Wu. 2007). Dephosphorylation 
of MAP kinases by MKPs inhibits MAPK activity, thereby negatively regulating MAPK 
signalling (Wu. 2007).  
The MKPs encompass a family of ten enzymes, with each one having distinct properties in 
terms of transcriptional regulation, subcellular localization, and substrate specificity (Staples 
et al. 2010). The first member of this family of enzymes to be discovered was the nuclear 
phosphatase, MKP-1 (Chu et al. 1996). It was initially characterized as an ERK1 and -2 
phosphatase but further research indicated that MKP-1 also had activity towards p38 and 
JNK MAPKs and it was capable of inactivating all three classes of MAPK in vivo (Groom et al. 
1996). 
The broad substrate selectivity is governed by the ability of MKP-1 to form physical 
complexes with ERK, p38 and JNK MAPKs. Hence, MAPK phosphatase-1 (MKP-1) is a mitogen 
and stress-inducible dual specificity protein phosphatase that has the ability to inactivate all 
three major classes of MAPK in mammalian cells (Staples et al. 2010). MKP-1 is believed to 
be involved in regulating the cell cycle (Wu. 2004; Yang and Wu. 2004) and apoptosis  
(Sanchez-Perez et al. 2000; Wang et al. 2006; Zhou et al. 2006),  since JNK,  p38,  and ERK are 
capable of either inducing apoptosis or cell proliferation. MKP-1 can be induced by stresses 
(Wang et al. 2006; Zhou et al. 2006) and plays a role in cellular protection against a variety of 
genotoxic insults including hydrogen peroxide, ionizing radiation and cisplatin 
(chemotherapeutic drug) treatment, and also mediates breast cancer chemoresistance (Rojo 
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et al. 2009). However, its role in the interaction between different MAPK pathways in 
determining cell death and survival is not fully understood (Staples et al. 2010). 
Recent studies have suggested that MKPs are involved in the development of cancer and 
play an important role in the response of cancer cells to chemotherapy. The role of MKPs in 
cancer stems from studies on MKP-1 expression in the different stages of various cancer 
types (Boutros et al. 2008; Wu. 2007). Numerous studies indicated that MKP-1 expression is 
altered in various cancer types including breast, lung, prostate, ovarian, pancreatic, gastric 
and liver cancer (Haagenson and Wu. 2010; Rojo et al. 2009). Furthermore, clinical studies 
have shown that MKP-1 expression correlates with cancer progression and can aid in 
prognosis. In human breast cancer, MKP-1 was found to be increased in malignant samples 
compared to non-malignant samples (Wang et al. 2003). MKP-1 expression was also 
increased in non-small cell lung cancer cells when compared to the normal lung (Vicent et al. 
2004).  
MKP-1 mRNA and protein levels were also found to be increased in pancreatic cancer; here 
MKP-1 down-regulation decreased pancreatic cancer cell growth and tumourigenicity in a 
nude mouse tumour model (Liao et al. 2003). To summarize: These findings indicate that 
MKP-1 plays a critical role in cancer development and may be a useful marker for predicting 
the survival of patients with cancer.  
Evidence is growing to suggest a role of MKP-1 as a mediator of acquired breast cancer 
chemoresistance in human cell lines. Rojo et al. (Rojo et al. 2009) provided evidence on the 
role of MKP-1 in human breast cancer at three levels: Firstly, MKP-1 is overexpressed during 
the malignant transformation of the breast; secondly, MKP-1 overexpression is linked to 
poor patient outcome and lastly MKP-1 can be repressed by doxorubicin in many human 
breast cancers. The repression of MKP-1 is proposed to be associated with increasing levels 
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of phospho-extracellular signal-regulated kinase 1/2 (ERK) and c-Jun NH2-terminal kinase 
(JNK) (Rojo et al. 2009). Their results add support to the concept that MKP-1 can act as a 
novel target for breast cancer therapy and also justify further studies on MKP-1 as promising 
prognostic marker. 
2.2.1 MKP-1 inhibition 
Evidence for the role of MKP-1 in cancer originates from a study by Liao et al. (Liao et al. 
2003) who showed that PANC-1 human pancreatic cells were unable to form tumours in 
nude mice following transfection with a full-length MKP-1 antisense construct (Liao et al. 
2003). The exact mechanism by which MKP-1 inhibition affects tumourigenicity remains 
unknown however.  
There is a lack of optimal small-molecule inhibitors for MKP-1 (Ding et al. 2002). Such 
compounds will be beneficial for improving the efficacy of anticancer agents during 
conditions of MKP-1 overexpression. The availability of a selective inhibitor for MKP-1 would 
prove to be a valuable tool for understanding the intricate processes involved in ERK,  JNK 
and p38 down-regulation,  and to outline the contribution of MKP-1 and its cellular targets 
to cancer progression. 
Since the three-dimensional structure for MKP-1 is still unknown, proper inhibitors are not 
available. However, several compounds have been found to block MKP-1 activity or protein 
function: Benzofuran blocks MKP-1 protein function (Lazo et al. 2006) and Ro 31-8220 
inhibits kinase activity and prevents protein expression (Beltman et al. 1996). An alkaloid 
plant extract, sanguinarine, (Vogt et al. 2005) has also been shown to inhibit MKP-1 activity.  
Sanguinarine is a bioactive quaternary benzophenanthridine alkaloid plant extract found in 
Sanguinaria Canadensis,  (blood root),  Poppy fumaria,  Bocconia frutescens,  Chelidonium 
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majus, and Macleya cordata and is a structural homologue of chelerythrine (Aburai et al. 
2010; Adhami et al. 2004; Das et al. 2004; Jang et al. 2009; Mackraj et al. 2008; Park et al. 
2010; Serafim et al. 2008; Vogt et al. 2005). A positive moiety is present in the aromatic ring 
of the sanguinarine molecule (Serafim et al. 2008) (Figure 2.2) and it is suggested that the 
core structure is a pharmacophore with rich potential for structural and functional 
modifications (Vogt et al. 2005).  
 
Figure 2.2: The molecular structure of Sanguinarine (Serafim et al. 2008) 
Sanguinarine extracts have long been used in herbal medicine and documented properties 
include antiviral, antimicrobial, antibacterial, anti-oxidant, anti-inflammatory and pro-
apoptotic activity (Jang et al. 2009; Vogt et al. 2005). Recent studies showed that 
sanguinarine can induce apoptosis in a variety of cancer cells through cell cycle arrest 
(Adhami et al. 2004) ,  caspase activation (Kim et al. 2008),  modulation of Bcl-2 (Ahsan et al. 
2007) and down-regulation of ERKs (Han et al. 2007;Jang et al. 2009). Sanguinarine is used in 
traditional medicine as a pain reliever, sedative, expectorant and for infections (Das et al. 
2004). It is also commonly used in toothpaste and various oral-hygiene products to combat 
gingivitis, inflammation and plaque formation (Adhami et al. 2004; Das et al. 2004). 
Sanguinarine has been reported to possess multiple cellular activities which include 
inhibition of nuclear factor κB (NF-κB), suppression of vascular endothelial growth factor-
induced angiogenesis and cell cycle arrest in G1/S and G2/M (Vogt et al. 2005). It 
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demonstrates activity in both the intrinsic and extrinsic apoptotic pathways in human 
promyelocytic leukaemia HL-60 cells (Vrba et al. 2009) and induces apoptosis in human 
squamous carcinoma (Ahmad et al. 2000).  These effects and a more recent finding stating 
that sanguinarine sensitized human cervical cancer cells selected for cisplatin resistance to 
cell death, led Vogt et al (2005) to discover that sanguinarine is an inhibitor of MKP-1. 
Sanguinarine treatment inhibited MKP-1 activity and consequently, increased phospho-ERK 
and phospho-JNK levels in a human pancreatic cell line, PANC1 (Vogt et al. 2005). This 
finding suggested a link between the sanguinarine-induced cell death and reduced MKP-1 
activity; however this still has to be further elucidated. 
2.2.2 MKP-1 induction 
Glucocorticoids have the ability to inhibit tumour necrosis factor α-induced apoptosis in 
subcutaneous adipocytes (Zhang et al. 2001), mediate cell survival in primary cultures of 
human and rat hepatocytes (Bailly-Maitre et al. 2001),  and protect against growth factor 
withdrawal-induced apoptosis in mammary epithelial cells (Wu et al. 2005). They observed 
that glucocorticoids have the ability to inhibit chemotherapy-induced apoptosis both in vitro 
(Wu et al. 2004) and in vivo (Herr et al. 2003).  
It is possible that the activation of the glucocorticoid receptor regulates numerous 
complementary signalling pathways that lead to cell survival. In light of this, dexamethasone, 
an anti-inflammatory glucocorticoid, was shown to induce MKP-1 and subsequently inhibit 
p38 MAPK phosphorylation in HeLa cells (Lasa et al. 2002). Increased MKP-1 gene expression 
and the attenuation of proteosomal degradation were also observed (Kassel et al. 2002).  
Dexamethasone has MKP-1 induction capabilities in several cell types including the RBL-2H3 
mast cells and NIH 3T3 fibroblast (Kassel et al. 2002),  HeLa cervical carcinoma (Lasa et al. 
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2002),  MBA-15.4 bone marrow stromal,  and the MG-63 pre-osteoblast cell lines 
(Engelbrecht et al. 2003). The rapid induction of MKP-1 by dexamethasone and the presence 
of three putative glucocorticoid response elements in the promoter region, suggested that 
MKP-1 is transcriptionally regulated by the glucocorticoid receptor (GR) (Kassel et al. 2002).  
Research has shown that MKP-1 is one of the consistently up-regulated genes that 
contribute to the GR mediated inhibition of apoptosis which led to the discovery that 
induction of MKP-1 by dexamethasone in breast cancer cells, inhibited paclitaxel induced 
apoptosis (Wu et al. 2004; Fan et al. 2004). Hence, the up-regulation of MKP-1 following 
glucocorticoid receptor activation plays an important role in inhibiting chemotherapy-
induced MAPK activation thus promoting cell survival and inhibiting apoptosis. 
2.3 Apoptosis 
The observation that cell death forms part of normal development was made more than a 
century ago. Only much later the term “programmed cell death” was used to describe the 
observation that some cells are intended to die as if driven by a cell-intrinsic program 
(Lockshin and Williams. 1965).  
The term ‘’apoptosis’’,  was first introduced in 1972 (Kerr et al. 1972),  and is defined as an 
evolutionary conserved, active process that leads to cell death mediated by programmed 
signalling pathways associated with a set of morphological features (Hengartner. 2000). It is 
characterized by typical morphological and biochemical hallmarks. Apoptosis occurs in both 
physiological and pathological situations and activation can be initiated by a variety of 
extracellular or intracellular stimuli. It describes unique morphological changes that include 
cytoplasm shrinkage, membrane blebbing, nuclear chromatin condensation, chromosomal 
DNA fragmentation and formation of apoptotic bodies, which are eventually phagocytosed 
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by macrophages and other neighbouring epithelial cells, resulting from the activation of 
apoptotic signalling pathways (Arends and Wyllie. 1991).  
A variety of cellular proteins are involved in the process of apoptosis. Among those, the 
proteolytic enzymes such as caspases are the well-established effector molecules and 
executioners of apoptosis (Cohen. 1997; Degterev et al. 2003). 
Anticancer therapies lead to the activation of caspases, a family of cysteine proteases acting 
as death effector molecules in cell death (Degterev et al. 2003). They are synthesized as 
inactive proforms and when activated cleave next to aspartate residues (Degterev et al. 
2003). The morphological features of cell death are mediated by caspases that cleave a 
variety of substrates in the cytoplasm or nucleus (Degterev et al. 2003). DNA fragmentation 
is mediated by ICAD (inhibitor of caspase-activated DNase) cleavage (Degterev et al. 2003). 
ICAD is an inhibitor of the endonuclease CAD (caspase-activated DNase) that cleaves DNA 
into the characteristic oligomeric fragments (Nagata. 2000). Proteolysis of cytoskeletal 
proteins leads to loss of cell shape and degradation of lamin results in nuclear shrinking 
(Degterev et al. 2003) (Figure 2.3, p17). 
Cellular suicide can be initiated either through the activation of the extrinsic (receptor) 
pathway or at the mitochondria through stimulation of the intrinsic pathway (Fulda and 
Debatin. 2006) (Figure 2.3, p17). Apoptosis is regulated by the cytosolic signalling platform of 
cell death, the apoptosome (Riedl and Salvesen. 2007), and regulatory proteins such as the 
family of inhibitors of apoptosis (IAP) and Bcl-2 (Jang et al. 2009).  
The first pathway – the extrinsic or cytoplasmic pathway – is triggered by the Fas death 
receptor, while the second pathway – the intrinsic or mitochondrial pathway – leads to the 
release of cytochrome c from the mitochondria and activation of the death signal (Ghobrial 
et al. 2005). The pathways finally converge to a common pathway that involves the 
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activation of a cascade of proteases that cleave regulatory and structural molecules 
culminating in cell death (Ghobrial et al. 2005). 
The extrinsic pathway encompasses several protein members including the death receptors, 
membrane-bound Fas ligand (Fas-L), Fas complexes, Fas associated death domain (FADD) 
and caspase 8 and 10, which leads to the activation of downstream caspases and ultimately 
results in apoptosis. Activation is initiated with the ligation of the death receptors (DRs) of 
the tumour necrosis factor (TNF) receptor superfamily or TNF-related apoptosis inducing 
ligand (TRAIL) receptors (Walczak and Krammer. 2000).  
Upon stimulation by a death signal, the membrane bound Fas-L interacts with the inactive 
Fas complexes and forms a death-inducing signalling complex. This complex consists of the 
adaptor protein Fas-associated death domain (FADD) protein and caspase 8 and 10 and leads 
to the activation of initiator caspase 8,  which ultimately propagates apoptosis by cleavage of 
the effector caspase 3 (Ghobrial et al. 2005; Park et al. 2010). The activation of caspase 8 
may be sufficient to execute death in some cell types; however, in other cell types, caspase 8 
interacts with the intrinsic apoptotic pathway via Bid cleavage and the subsequent release of 
cytochrome-c (Ghobrial et al. 2005). 
The Bcl-2 family of proteins are important regulators of the intrinsic pathway. Bcl-2 
overexpression causes resistance to chemotherapeutic drugs and radiation via the 
accumulation of cells in the G0 phase, while a decrease in Bcl-2 expression promotes the 
apoptotic response (Ghobrial et al. 2005). The Bcl-2 family includes both pro- and anti-
apoptotic members. The anti-apoptotic Bcl-2 members - Bcl-2, Bcl-XL, Bcl-W, Bfl-1, and Mcl-1 
- repress apoptosis by hindering the release of cytochrome c.  
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The pro-apoptotic members act as promoters of apoptosis and they include: Bax, Bak, Bad, 
Bcl-Xs, Bid, Bik, Bim and Hrk (Ghobrial et al. 2005; Park et al. 2010). Proapoptotic proteins 
undergo posttranslational modifications following a death signal. These modifications 
include activation via dephosphorylation and cleavage which results in translocation to the 
mitochondria and finally apoptosis (Ghobrial et al. 2005).  
The mitochondrial pathway is initiated by the release of cytochrome c, apoptosis inducing 
factor (AIF), Smac/DIABLO (second mitochondria derived activator of caspase/direct 
inhibitor of apoptosis protein (IAP)-binding protein with low PI) or endonuclease G from the 
mitochondrial intermembrane space (Fulda and Debatin. 2006; Park et al. 2010). Upon 
apoptotic stimuli, cytochrome c and Smac/DIABLO is released through the permeable outer 
mitochondrial membrane. Cytochrome c release into the cytosol triggers caspase 3 
activation by the formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome 
complex (Fulda and Debatin. 2006), whilst Smac/DIABLO promotes caspase activation via the 
neutralization of the inhibitory effects to the IAPs (Fulda and Debatin. 2006; Gerl and Vaux. 
2005). Caspase 9 then becomes proteolytically active and in turn activates caspase 3 which 
results in the activation of downstream caspases and subsequently leads to apoptosis 
(Ghobrial et al. 2005).  
The two pathways converge at caspase 3, where cleavage of the inhibitor of the caspase-
activated deoxyribonuclease (ICAD) activates the caspase-activated deoxyribonuclease 
(CAD), leading to nuclear apoptosis. The upstream caspases 9 and 8 converge on caspase 3 in 
the intrinsic and extrinsic pathways respectively. Cleavage of protein kinases, cytoskeletal 
proteins, DNA repair proteins, inhibitory sub-units of endonucleases (CIDE family) and the 
destruction of housekeeping cellular functions are all mediated by the downstream 
caspases. The effect of caspases on cytoskeletal structure, cell cycle regulation and signalling 
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pathways ultimately leads to the characteristic morphological changes associated with 
apoptosis such as DNA condensation and fragmentation, and membrane blebbing (Ghobrial 
et al. 2005) (Figure 2.3). 
 
 
 
 
Figure 2.3: Apoptosis signalling pathway. Adapted from Ghobrial et al. 2005. 
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PARP cleavage is another hallmark of apoptosis. PARP binds to DNA fragments in response 
to DNA fragmentation and this catalyses the poly (ADP)-ribosylation of many proteins 
through converting nicotinamide adenine dinucleotide (NAD) to nitric acid monohydrate 
(NAM) and ADP-ribose (Zong and Thompson. 2006). PARP depletes cytosolic NAD during this 
process, as cytosolic and mitochondrial NAD do not exchange freely across the inner 
mitochondrial membrane (Zong and Thompson. 2006). If glucose breakdown is inhibited, the 
activation of PARP could induce necrosis, unless NAD pools are replenished (Zong and 
Thompson. 2006). Thus, PARP cleavage by caspases prevents energy depletion and the 
induction of necrosis; hence, caspases are not only important in the regulation of apoptosis 
but also in the inhibition of necrosis (Zong and Thompson. 2006). 
Links between the receptor and mitochondrial pathway have been proposed at different 
levels. The activation of caspase 8 can result in cleavage of Bid, a protein from the Bcl-2 
family, which translocates to the mitochondria to release cytochrome c and thereby initiate 
a mitochondrial amplification loop (Cory and Adams. 2002). Cleavage of caspase 6 
downstream of the mitochondria may feed back to the receptor pathway by cleaving 
caspase 8 (Cowling and Downward. 2002). 
Apoptosis is imperative in the maintenance of normal homeostasis and acts in concert with 
other processes like proliferation and differentiation. Dysregulation of the apoptotic 
machinery has disastrous consequences and is associated with many diseases such as 
cancer, auto-immunity and neuro-degeneration (Ghobrial et al. 2005). 
It is well-known that anticancer agents such as chemotherapy, γ-irradiation or 
immunotherapy exert their antitumour effect by inducing apoptosis, and that the disruption 
of apoptotic processes can reduce the sensitivity of cancer to treatment (Fulda and Debatin. 
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2006). The underlying mechanism that initiates an apoptotic response following cytotoxic 
therapy depends on the individual stimulus and has often not yet been identified.  
Nevertheless, a common initial event is considered to be damage to DNA which is then 
propagated by the cellular stress response (Fulda and Debatin. 2006). Stress inducible 
molecules such as JNK, ERK, NF-κB or ceramide have been inferred to transmit the apoptotic 
signal in cancer therapy (Fulda and Debatin. 2006). 
Apoptosis pathways have to be tightly controlled, and various anti-apoptotic mechanisms, 
such as mutations in apoptotic programs, have been associated with resistance to 
therapeutic agents in cancer cells. However,  the notion that apoptosis is the major form of 
cell death by which cancer cells die should not be applied to all cancers as caspase 
independent apoptosis and other modes of cell death,  including autophagy,  have also been 
implicated in response to cancer therapy in certain instances (Brown and Wilson. 2003). 
2.3.1 The role of MKP-1 signalling in apoptosis 
Several studies have shown that MKP-1 inhibits cell death induced by a number of anti-
cancer drugs in different cancer cells. It has been shown to inhibit biochemical events 
associated with apoptosis, such as the activation of caspase-3 and proteolytic cleavage of 
poly (ADP ribose) polymerase (PARP). These findings indicate the MKP-1 acts at a site 
upstream of caspase activation within the apoptotic program (Franklin et al. 1998).  
It is proposed that caspase 3/7 is responsible for the activation of MAPKs, such as ERK1/2, 
p38 MAPK and JNK, via Mst1, an upstream kinase for MAPKKK, through an extrinsic 
apoptotic pathway-dependent mechanism (Song and Lee. 2008). 
According to Song and Lee (2008), caspase 7 cleaves Mst1; thereby producing a 40 kD 
fragment which subsequently activates JNK and p38 MAPK, and caspase 3 produces a 36 kD 
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fragment of Mst1 responsible for the activation of ERK (Song and Lee. 2008). However, the 
functional significance of MAPK activation in this scenario still needs further investigation. If 
MKP-1 expression is upregulated in certain instances then its inhibitory effects on JNK, p38 
MAPK and ERK demolishes the activation induced by caspase 3/7.  
MKP-1 has been implicated in anti-apoptotic effects observed in mouse embryonic 
fibroblasts (MEFs) in the presence of anisomycin by suppressing caspase-3-mediated 
apoptosis (Wu and Bennett. 2005). Furthermore, Wang et al., (2006) indicated that cisplatin 
treatment activates PARP and caspase 3 in MKP-1-null MEFs by inducing their cleavage 
which resulted in an increase in caspase 3 activity. This effect was, however, not seen in 
wild-type MEFs when treated similarly (Wang et al. 2006). Moreover, MKP-1 expression via 
transfection or adenoviral transduction reduced the increase in caspase 3/7 activity 
mediated by paclitaxel (Jordan and Wilson. 2004) and mechlorethamine in MDA-MB231 cells 
(Small et al. 2007).  
A similar effect was seen in BT-474 and A1N4-myc cells where adenovirus-mediated 
expression of MKP-1 reduced DNA fragmentation following doxorubicin, paclitaxel or 
mechlorethamine treatment (Boutros et al. 2008). These results mirror those derived from 
treating wildtype MEFs and MKP-1 null MEFs with doxorubicin, paclitaxel, or 
mechlorethamine (Small et al. 2007).  
To summarise, these findings indicated that in the presence of MKP-1, human mammary 
epithelial cells, breast carcinoma cells, and MEFs are protected from agents that induce DNA 
fragmentation through a JNK/c-Jun-mediated mechanism (Small et al. 2007). This suggests a 
role for MKP-1 in inhibiting apoptosis in these scenarios. 
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MKP-1 protein levels were found to be increased in human primary gastric tumours, when 
compared with normal gastric tissues (Bang et al. 1998). In these tumours ERK1/2 activity 
was elevated compared with patient matched normal gastric tissue and the authors believed 
that the increase in MKP-1 expression was a consequence of increased ERK1/2 activity and 
that it contributed to carcinogenesis (Bang et al. 1998). Liu et al. (1995) found that short-
wavelength ultraviolet light (UVC) up-regulates ERK2 and JNK1 activity in HeLa cells, causing 
an increase in MKP-1 protein levels; this led to a subsequent down-regulation of JNK activity 
in these cells. Also, in U937 human leukaemia cells, a study on the effect of MKP-1 on UVC 
induced cell death indicated that MKP-1 overexpression reduced JNK-mediated apoptosis in 
these cells (Franklin et al. 1998). Low doses of UVC also decreased MKP-1 mRNA in 
transcription coupled repair-deficient human fibroblasts (Hamdi et al. 2005). These findings 
indicate that MKP-1 can protect cells from chemical- and radiation induced JNK activation. If 
one considers the protective effect MKP-1 has in certain tumour cell lines, it would make 
sense to investigate whether this effect is indeed demolished if MKP-1 is down-regulated or 
inhibited prior to the use of chemotherapeutic agents. Thus, understanding the role of MKP-
1 in cancer development and its impact on chemotherapy can be exploited for therapeutic 
benefits for the treatment of cancer. 
2.4 Autophagy 
Many chemotherapy drugs, such as doxorubicin (Roninson et al. 2001), arsenic trioxide  
(Kanzawa et al. 2003) and cisplatin (Yang et al. 2008) are known to induce an autophagic 
response in cancer cells (de Bruin and Medema. 2008; Yousefi and Simon. 2009). Autophagy 
(Figure 2.4, p 23), first described in the 1960’s, is a genetically regulated process that plays a 
critical role in the degradation of cytoplasmic proteins and other macromolecules 
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(Stromhaug and Klionsky. 2001). This occurs via their sequestration within autophagosomes 
which subsequently fuse with lysosomes in multicellular organisms (Yang et al. 2008).  
Autophagy is initiated by the induction of several genes in the autophagy network including 
LC3, phosphatidylinositide 3-kinase and Beclin 1 (Yang et al. 2008). This occurs mainly in 
response to nutrient starvation, hypoxia, ATP depletion or signals prompting cellular 
remodelling and is controlled by the mTOR pathway (Meijer and Codogno. 2004). Autophagy 
is a highly regulated process that can be either generally involved in the turnover of long-
lived proteins and organelles or can specifically target distinct organelles and thereby 
eliminate damaged cellular constituents (Maiuri et al. 2007). 
During autophagy, parts of the cytoplasm and intracellular organelles are sequestered within 
the double-membraned autophagosomes before being delivered to lysosomes (Maiuri et al. 
2007), a process regulated by the Atg genes (Hoyer-Hansen and Jaattela. 2008). 
Subsequently, the autophagosomes fuse with the lysosomes to form autophagolysosomes, 
where the sequestered material is digested (Maiuri et al. 2007). The initial step of autophagy 
can be regulated by class I and class III phosphoinositide 3 kinases (PI3K) (Hsieh et al. 2009). 
Activation of class I PI3K inhibits autophagy through successive phosphorylation of Akt and 
mTOR, while activation of class III PI3K in a complex with Beclin 1 promotes autophagy 
(Hsieh et al. 2009). 
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Figure 2.4: Induction of autophagy requires interaction between beclin 1 and class III phosphoinositide 3 kinase (PI3K III). 
Bcl-2 can bind to beclin 1 and inhibit autophagy. Autophagy is also negatively regulated by mTOR. Atg proteins are 
recruited to the membrane via nucleation and elongation of the membrane is initiated by the Atg12/Atg5/Atg16 
complex. LC3 is cleaved by Atg 4 to generate LC3-I. LC3-I is then activated by the Atg7/Atg4/Atg3 complex. The resulting 
LC3-II then finalizes the formation of the autophagosome. P62 is responsible for the sequestration of the autophagy 
substrates into larger units or aggregates. Via the interaction with LC3-II through the LC3 interacting region (LIR), the 
phagophore is recruited and the autophagosome forms around the aggregated substrates (Moscat et al. 2009). Fusion to 
and incorporation of the lysosome creates the autophagolysosome which results in the degradation of the contents 
through hydrolase activities. Adapted from www.cellsignal.com/reference/pathway/Autophagy.html 
 
  
Autophagy plays a role in regulating cell death in both physiological and pathophysiological 
conditions (Kundu and Thompson. 2008; Levine and Yuan. 2005).  Under normal conditions, 
basal autophagy has been proposed as a mechanism for protein turnover and the 
elimination of damaged or aged organelles and cytoplasmic components to maintain 
homeostasis in the cell. Autophagic induction under pathological conditions is considered to 
be a pro-survival mechanism; however, extensive autophagy or inappropriate activation of 
autophagy results in cell death by bulk elimination of organelles (Yang and Wu. 2004). 
6P62 
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Autophagic cell death is different from apoptosis in the sense that it is caspase-independent 
and can occur even if the apoptosis machinery of the cell is defective (Shimizu et al. 2004). 
There is considerable controversy as to whether autophagy actually protects cells from 
death or causes cell death (Lockshin and Zakeri. 2004). Some researchers argue that the role 
of autophagy depends on the state of the cell, where initially, following a cellular stress, 
autophagy acts as a protective mechanism, but ultimately it results in the accumulation of 
cellular constituents in lysosomes and cell death (Cuervo. 2004).  
Autophagy has been proposed as a mechanism for both tumour progression and tumour 
suppression, although the exact mechanism responsible for this dual action in cancer has not 
been fully elucidated (Salazar et al. 2009). Even though it is now widely accepted as a form 
of programmed cell death (Lockshin and Zakeri. 2004),  many still believe that it might more 
accurately be described as a cell survival mechanism that acts alongside cell death but does 
not necessarily lead to it (Tsujimoto and Shimizu. 2005). 
During tumorigenesis normal cells are transformed into cancerous cells through the 
accumulation of gene mutations and epigenetic modifications (Folkman. 2006). These cells 
experience severe metabolic stress conditions since oxygen, growth factors and nutrients 
cannot diffuse efficiently to the cells at the centre of the tumour due to inadequate 
vascularisation (Folkman. 2006). 
As a result, the cells at the centre of the tumour live in a metabolically stressed environment 
characterized by hypoxia, low pH and nutrient deprivation, all of which induces autophagy 
(Jin and White. 2008). Autophagy is thus localized to these metabolically stressed regions 
where it functions to support cell survival (Jin and White. 2008). This explains why some 
cancer cells have a high basal level of autophagy to begin with. Extensive activation of 
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autophagy in cancer cells lead to the disintegration of major cellular systems in such a way 
that the “point of no return” is crossed and cell recovery is unachievable (Eisenberg-Lerner 
and Kimchi. 2009). Therefore, autophagy can protect cells against death or mediate cell 
death depending on the autophagy stimuli and cellular context. It has been shown that a 
deficiency in autophagy can lead to cancer development.  
Some breast cancer cell lines contain deletions in Beclin 1, which is required to induce 
autophagy (Liang et al. 1999). Introduction of Beclin 1 into these cell lines induced 
autophagy and inhibited tumorigenecity which has led to the conclusion that the deletion of 
Beclin 1 might contribute to the progression of breast cancer (Liang et al. 1999). 
2.4.1 Autophagy and MKP-1 
Little is known about the role of MKP-1 in autophagy. The only direct link found between 
MKP-1 and autophagy was discovered recently when it was observed that an areca nut 
extract (ANE), a carcinogen and addictive substance often used in Asia, causes induction of 
autophagy, which was mediated through p38 MAPK and MKP-1 activation, in oral cancer 
cells. ANE-induced autophagy inhibited apoptosis in this scenario (Lu et al. 2010). 
2.5 Crosstalk between autophagy and apoptosis 
When viewed dynamically, autophagy acts to delay cell death and only leads to it in a last 
desperate effort while attempting to keep the cell alive. We believe that this can only occur 
once autophagy has progressed and persisted beyond the so-called “point of no return”, 
resulting in apoptosis or possibly necrosis (Loos and Engelbrecht. 2009). 
Crosstalk between autophagy and apoptosis is a dynamic physiological relationship. The 
relationship is complex in the sense that, in some scenarios, autophagy acts as a stress 
adaptation that helps to avoid cell death, whereas in other settings, it constitutes an 
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alternative pathway to cell death that is also referred to as autophagic cell death or type II 
cell death (de Bruin and Medema. 2008). In general terms it appears that autophagy and 
apoptosis can be induced by similar stimuli (Maiuri et al. 2007). This has been proved by the 
recent deciphering of pathways that link the autophagic and apoptotic machinery (Maiuri et 
al. 2007). Bcl-2 family proteins, consisting of pro- and anti-apoptotic proteins, are important 
regulators of apoptosis and autophagy (Igney and Krammer. 2002). Beclin-1 has a Bcl-2 
binding domain and this domain serves as a point of crosstalk between autophagic and 
apoptotic pathways at the point of autophagic induction (Shimizu et al. 2004). The 
dissociation of Beclin 1 from anti-apoptotic Bcl-2 is essential for its autophagic activity; 
failure of dissociation results in autophagy being suppressed (Pattingre and Levine. 2006). 
The transcription factor, p53, is also linked to both autophagy and apoptosis. It is a well-
known apoptosis inducer, but recent evidence has also linked it to autophagy through the 
inhibition of mTOR via AMPK (Tasdemir et al. 2008). 
These pathways are thus regulated by certain common factors and share common 
components, each of which can possibly regulate and modify the activity of the other. 
Apoptosis and autophagy thus constitute the two processes through which damaged or aged 
cells and organelles are eliminated. 
The availability of ATP is necessary for apoptosis as it is an energy dependent process (Leist 
et al. 1999). Lack of ATP would favour necrosis; therefore autophagy is required for tumour 
cells to undergo apoptosis as it provides ATP. Initially autophagy provides ATP and nutrients 
to tumour cells, but as the degree of autophagy increases it will eventually lead to cell death 
(Levine. 2007). 
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2.6 Treatment options for breast cancer 
The anthracycline antibiotic, doxorubicin is one of the most important anticancer agents for 
a variety of solid tumours and leukaemias (Hortobagyi. 1997). It is generally accepted that 
the primary cytotoxic mechanism of doxorubicin can be attributed to its ability to intercalate 
with the cell’s DNA and cause localized uncoiling of the double helix. It can also stabilize the 
complex between DNA and topoisomerase II which results in the subsequent induction of 
apoptosis (Cuvillier et al. 2001; Wang et al. 2004). It has the ability to generate reactive 
oxygen species from quinone-generated redox activity that also results in DNA degradation 
(Cuvillier et al. 2001; Wang et al. 2004). Interestingly, doxorubicin has also been shown to 
induce an autophagic response prior to the induction of apoptosis (Roninson et al. 2001).  
One of the major goals in cancer research is to increase the susceptibility of cancer cells to 
apoptosis-based strategies. However, in some instances, the resistance to chemotherapy 
could not only be attributed to their inability to induce apoptosis, but also to the protection 
exerted by autophagy.  
Furthermore, it has also been demonstrated that in some cases, breast cancers are highly 
resistant to doxorubicin treatment (Smith et al. 2006) which represents a major obstacle in 
successful treatment. The precise molecular sequences responsible for this resistance are 
unknown, but it is suggested that resistance occurs through the expression of a membrane 
transporter, P-glycoprotein/ MDR1 that pumps the drug out of the cell and generates 
reactive oxygen species and free radicals via Doxorubicin redox cycling (Finn et al. 2011). 
2.7 Sensitizing breast cancer cells to cell death 
It would be of great benefit to find adjuvant therapeutic targets that will be effective in 
inducing cell death in cancer cells without further harming normal cells. Evidence suggesting 
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that MKP-1 is overexpressed in breast cancer is accumulating; therefore targeting this 
protein can be a novel avenue for therapeutic intervention.  
We, therefore, propose that by inhibiting MKP-1 with sanguinarine and inducing autophagy 
with doxorubicin, the already high basal level of autophagy in breast cancer cells will 
increase and move closer to the “point of no return.” Subsequently, as the “point of no 
return” is reached, apoptosis will be induced, thereby sensitizing the cells to chemotherapy.  
Using combined doxorubicin and MKP-1 inhibition therapy to sensitize breast cancer cells to 
autophagy and bring them closer to the “point of no return” may prove to be a novel more 
effective treatment strategy for breast cancer patients. Recent studies have shown that 
autophagy can sensitize cancer cells to chemotherapeutic agents (Zhuang et al. 2009) as well 
as augment chemotherapy-induced apoptosis (Shimgu et al. 2009). It has been confirmed 
that doxorubicin induces an autophagy response in cancer cells. However, the effect of 
doxorubicin treatment in conjunction with sanguinarine in MDA-MB231 cells as well as in an 
in vivo mouse model still needs to be elucidated.  
2.8 Hypothesis 
We hypothesize that the inhibition of MKP-1, using a chemical inhibitor or siRNA, will 
increase the cytotoxic effect of doxorubicin (chemotherapeutic drug) in breast cancer cells 
thus making the cells more responsive to treatment which will lead to increased cell death 
through autophagy and apoptosis. 
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2.9 Aims 
 First, to determine a dose for doxorubicin to induce apoptosis in breast cancer cells 
(MDA-MB231). 
 Secondly, to characterize the effect of doxorubicin treatment on apoptosis under 
conditions of MKP-1 induction and inhibition to determine the functional role of 
MKP-1 in apoptosis. 
 Thirdly, to determine the level of MKP-1 expression in breast cancer cells treated 
with a MKP-1 inducer (dexamethasone), MKP-1 inhibitors (sanguinarine or MKP-1 
siRNA) and doxorubicin. 
 Fourthly, inhibit (sanguinarine, MKP-1 siRNA) and induce (dexamethasone) MKP-1 to 
determine the role of MKP-1 in autophagy during doxorubicin treatment in breast 
cancer. 
 Fifthly, to determine whether inhibiting MKP-1, with siRNA or sanguinarine, will 
improve the cytotoxic effect of doxorubicin in breast cancer cells. 
 Finally, to determine the effect of MKP-1 inhibition, with sanguinarine, and combined 
doxorubicin treatment on autophagy and apoptosis in vivo in C57BL6 tumour bearing 
mice. 
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Dexamethasone 
(100 nM) 
Sanguinarine  
(0.5 µM) 
Doxorubicin (5 µM) 
   MKP-1 
+ 
Autophagy MKP-1 Apoptosis 
• Western blot – LC3, p62  
• Flow cytometry - 
Lysotracker 
• Western blot – MKP-1 • Hoechst 33342 
• Western blot – Caspase 
3,  Cleaved PARP 
• Trypan Blue 
• Caspase Glo Assay 
siRNA 
-  +  
Chapter 3: 
Materials and Methods 
3.1 Study design   
MDA-MB231 cells 
Figure 3.1: Study design: MKP-1 was inhibited or silenced in MDA-MB231 breast carcinoma cells by using either Sanguinarine or 
MKP-1 siRNA. After MKP-1 inhibition the cells were treated with doxorubicin and autophagy and apoptosis were detected by 
various methods. MKP-1 inhibition was compared to a known inducer of MKP-1 namely dexamethasone. MKP-1 induction and 
inhibition was detected by means of western blotting.  
Stellenbosch University  http://scholar.sun.ac.za
 31 
3.2  Cell culture 
The human metastatic mammary carcinoma cell line, 
MDA-MB231, was used to perform experiments and was 
obtained from American Type Culture Collection 
(Rockville, MD, USA). The cells were cultured in 
Glutamax-Dulbecco’s Modified Eagle’s Medium 
(Glutamax-DMEM) (Celtic Molecular Diagnostics, Cape 
Town, South Africa) and supplemented with 10% Foetal 
Bovine Serum (FBS) (Sigma Chemical Co., St Louis, MO, USA), hereafter collectively referred 
to as growth medium. The cells were cultured in T75 flasks (75 cm2 flasks, Greiner Bio One, 
Germany) and maintained at 37°C in a humidified 5% CO2 atmosphere and were routinely 
sub-cultured upon reaching 70 – 80% confluency. The MDA-MB231 cells were allowed to 
grow in the T75 flasks until they reached 80% confluency and were then split and seeded 
into appropriate plates or dishes with new growth medium for various experiments. Splitting 
was accomplished by washing the cell monolayer with warm sterile Phosphate Buffered 
Saline (PBS), followed by incubation with 4 ml 0.25% Trypsin EDTA (Sigma Chemical Co., St 
Louis, MO, USA) at 37°C until cells detached completely from the surface of the flask. All 
experiments were performed using exponentially growing cells. A complete step by step 
protocol of MDA-MB231 cell culture procedures is included in Appendix A. 
3.3  Experimental protocol 
MDA-MB231 cells were allowed to grow and become confluent before they were split and 
seeded accordingly for each experiment. Seeding densities were previously determined for 
each experiment so that equivalent sub-confluent cell populations were always present at the 
Figure 3.2: The human metastatic 
mammary carcinoma cell line, 
MDA-MB231, was obtained from 
a patient in 1973 at M.D 
Anderson Cancer Center 
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time of treatment. The cells were randomly divided into treatment groups (see Table 1) and 
each group were treated as depicted in Figure 3.3 (p 34).  
 
Table 1: MDA-MB231 cells were divided into ten groups and each group were treated 
accordingly. 
Group number Group name Treatment 
Group 1 Control No treatment 
Group 2 
Dexamethasone 
Control 
Dexamethasone 
Group 3 
Dexamethasone and 
Doxorubicin 
Dexamethasone 
Doxorubicin 
Group 4 Doxorubicin Doxorubicin 
Group 5 Sanguinarine Sanguinarine 
Group 6 
Sanguinarine and 
Doxorubicin 
Sanguinarine 
Doxorubicin 
Group 7 MKP-1 siRNA MKP-1 siRNA 
Group 8 
MKP-1 siRNA and 
Doxorubicin 
MKP-1 siRNA 
Doxorubicin 
Group 9 Negative Control Stealth RNAi 
Group 10 Vehicle Methanol 
3.3.1  Treatment preparations 
MDA-MB231 cells were treated with Doxorubicin hydrochloride (D1515, Sigma Chemical Co., 
St Louis, MO, USA) for 24 hours at a concentration of 5 µM. The drug was dissolved in 
Glutamax-DMEM in ready to use aliquots to avoid freeze thaw cycles, and was stored at  
-20°C. Sanguinarine was used as a MKP-1 inhibitor. The cells were treated with Sanguinarine 
(Sigma Chemical Co., St Louis, MO, USA) at a concentration of 0.5 µM for 24 hours before 
doxorubicin treatment started. The drug was dissolved in methanol and stored as a 0.01 M 
stock solution at 4°C. To determine the extent to which sanguinarine and MKP-1 siRNA 
inhibited MKP-1, it was compared to a known inducer of MKP-1, dexamethasone (Sigma 
Chemical Co., St Louis, MO, USA). MDA-MB231 cells were treated with dexamethasone at a 
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concentration of 100 nM for 24 hours. Dexamethasone was dissolved in distilled water and 
stored as a 0.1 M stock solution at 4°C. Methanol made up in the same concentration as 
Sanguinarine was used as vehicle. The growth medium of all groups was refreshed before 
treatment started. The concentrations of the various treatments were selected based on 
assessment by dose-response experiments. 
3.3.2   MKP-1 siRNA Transfection 
For groups 7, 8 and 9 the cells were transfected through a reverse transcription protocol 
(Appendix A). Twenty pmol of MKP-1 siRNA duplex was used per culture well. Twenty pmol 
of both MKP-1 siRNA duplexes (DUSP1VHS40581 and DUSP1VHS40583) (Invitrogen™, USA, 
MKP-1 siRNA #159527B10, #159527B11) was diluted into 250 μl of transfection medium 
(Glutamax-DMEM containing no antibiotics or serum). 2 μl of Lipofectamine™ RNAiMAX 
(13778075; Invitrogen™, USA) was added to this and the suspension was gently mixed. The 
RNAi duplex-Lipofectamine RNAiMAX complexes were allowed to incubate for 40 minutes 
and then made up to a final volume of 2 ml using Glutamax-DMEM (no antibiotics). MDA-
MB231 cells were plated directly into the culture dishes containing the RNAi duplex-
Lipofectamine RNAiMAX complexes. Stealth™ RNAi (STEALTH RNAI NEG CTL MED GC, 
12935300; Invitrogen™, USA) was used as a negative control. Cells were incubated at 37°C 
and treated with doxorubicin 48 hours later. 
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 Groups 1-10: Seed 
Groups 7-9: siRNA 
 
 0 Hours 
Group 6: Sanguinarine 
(0.5 µM) 
 24 Hours  48 Hours 
Group 1, 7, 9: Refresh growth medium 
Group 2: Dexamethasone (100 nM) 
Group 3: Doxorubicin (5 µM) 
   Dexamethasone (100 nM) 
Group 4, 6, 8: Doxorubicin (5 µM) 
Group 5: Sanguinarine (0.5 µM)  
Group 10: Methanol 
Analyze all 
groups 
 72 Hours 
Treat cells 
Analyze cells 
Figure 3.3: Experimental plan for treatment of MDA-MB231 breast cancer cells. A 72 hour treatment time was followed from seeding up to analysis. All groups were seeded at 0 hours and 
reverse transfection was done for groups 7-9. Twenty-four hours later Group 6 was treated with Sanguinarine. At 48 hours the remaining groups were treated and growth medium was 
refreshed for non-treatment groups.  At 72 hours all treatment was stopped and data was analysed. 
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3.4 Determination of cell death 
3.4.1  Morphological analysis 
For morphological determination of cell death, MDA-MB231 cells were stained with Hoechst 
33342 (10 mg/ml) in a 1:200 dilution. Hoechst 33342 is able to diffuse through cell 
membranes regardless of their condition. It is a DNA stain that detects early apoptosis and 
stains the nuclei blue. MDA-MB231 cells were randomly divided into groups and seeded in 8-
well chambers (Greiner Bio One) at a seeding density of 3000 cells per well. For the groups 
that needed transfection, the cells were reverse transfected during plating (Section 3.3.2, 
p33). The cells were left to plate and grow in 200 µl growth medium per well and the 
experimental plan set out in Figure 3.3 was followed. Growth medium for all groups was 
changed and replaced with fresh growth medium before the indicated treatment (Section 
3.3.1, p 32) (Figure 3.3, p 34) started. The treatment was administered straight into the 
medium at the correct concentration. After treatment of the groups as described in section 
3.3.1, the medium was drained and the cell monolayer was washed with warm sterile PBS. 
Hoechst 33342 (1:200 dilution) was made up in growth medium and 200 µl growth 
medium/Hoechst solution was added to each well to cover the entire monolayer. The cells 
were left to incubate for 5 minutes. Images were acquired directly after the incubation 
period through an Olympus Cell® system attached to an IX-81 inverted fluorescence 
microscope equipped with an F-view-II cooled CCD camera (Soft Imaging Systems). By using 
a Xenon-Arc burner (Olympus Biosystems GMBH) as light source, images were excited with 
the 360 nm DAPI excitation filter. Emission was collected using a UBG triple band pass 
emission filter cube. Images were processed and background subtracted using the Cell® 
software. Images were taken of a minimum of three randomly chosen fields, of at least three 
independent experiments per treatment group. Morphological changes such as condensed 
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nuclear chromatin and apoptotic bodies were quantified using the Cell® system. A complete 
step by step protocol for Hoechst 33342 staining is reproduced in Appendix A (p 109).  
3.4.2   Trypan blue assay 
To determine the viability of MDA-MB231 cells after treatment, the Trypan blue exclusion 
technique (Kitakaze et al., 1997) was used. Due to an intact, functional cellular membrane 
viable cells are able to exclude the blue dye, whilst non-viable cells are unable to prevent its 
entrance into the cytoplasm as a result of membrane leakage. MDA-MB231 cells were 
randomly divided into groups and seeded in 6-well cell culture plates (Greiner Bio One) at a 
seeding density of 100 000 cells per well. For the groups that needed transfection, the cells 
were reverse transfected during plating (Section 3.3.2, p 33). The cells were left to plate and 
grow in 2 ml growth medium per well and the experimental plan set out in Figure 3.3 (p 34) 
was followed. Growth medium for all groups were changed and replaced with fresh growth 
medium before the indicated treatment (Section 3.3.1, p 32) (Figure 3.3) started. The 
treatment was administered straight into the medium at the correct concentration. 
Following completion of the treatment protocol as described in section 3.3.1, the medium 
was drained and the cell monolayer was rinsed with warm sterile PBS. The medium from 
each well was drained into ten sterile 15 ml Falcon tubes (Greiner Bio One), labelled 
according to treatment. Cells were trypsinized for approximately 3 minutes or until they 
detached from the surface of the flask and each cell suspension was added to the 
appropriate 15 ml Falcon tube and centrifuged for 3 minutes at 1500 rpm. The supernatant 
was decanted and the pellet resuspended in PBS. 50 μl cell suspension was mixed with 50 μl 
0.4% trypan blue and loaded into a haemocytometer for counting.  The amount of blue cells and 
total cells were counted and results were expressed as the percentage (%) of viable cells. A 
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minimum of three counts per treatment group of at least 3 independent experiments was done. 
A complete step by step protocol for Trypan blue assay is reproduced in Appendix A (p 107). 
3.4.3   Caspase 3/7 activity assay 
The Caspase-3/7 activity was measured in MDA-MB231 cells using the Caspase-Glo® 3/7 assay 
(Promega, Madison, WI, USA). MDA-MB231 cells were randomly divided into groups and 
seeded in 96-well micro titer plates (Greiner Bio One) at a seeding density of 5 000 cells per 
well. For the groups that needed transfection, the cells were reverse transfected during 
plating (Section 3.3.2, p 33). The cells were left to plate and grow in 100 µl growth medium 
per well and the experimental plan set out in Figure 3.3 was followed. Growth medium for 
all groups were changed and replaced with fresh growth medium before the indicated 
treatment (Section 3.3.1, p32) (Figure 3.3, p 34) started.  The Caspase-Glo® 3/7 reagent was 
prepared and equilibrated at room temperature and mixed with the lyophilized substrate before 
the reconstituted working buffer reagent was stored at -20°C.  The working buffer reagent was 
allowed to equilibrate to room temperature prior to use. The 96-well micro titer plate was also 
allowed to equilibrate to room temperature 10 minutes prior to the assay.  100 μl of working 
buffer reagent was then added to each well containing cells where after the plate was incubated 
in the dark at 22°C for one hour. The content of each well was transferred to a white-walled 96-
well plate and the luminescence was measured using a luminometer. 
3.4.4  Western blot analysis of Caspase 3 and Cleaved PARP 
For Western blotting MDA-MB231 cells were randomly divided into groups and seeded in  
6 well plates at a seeding density of 100 000 cells per well. For the groups that needed 
transfection, the cells were reverse transfected during plating (Section 3.3.2, p33). The cells 
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were left to plate and grow in 2 ml growth medium per well and the experimental plan set 
out in Figure 3.3 was followed. Growth medium for all groups were changed and replaced 
with fresh growth medium before the indicated treatment (Section 3.3.1, p 32) (Figure 3.3, 
p34) started. The treatment was administered straight into the medium at the correct 
concentration. 
3.4.4.1 Protein extraction and quantification 
After treatment of the groups as described in section 3.3.1, cells were drained and placed on 
ice. Cell monolayers were then rinsed three times with 1 ml cold PBS. Total cell protein was 
then extracted by incubating the cells for 5 minutes in 200 µl of a modified radio-immuno 
precipitation (RIPA) buffer, pH 7.4, containing: 50 mM Tris-HCL, 1 mM EDTA, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM benzamidine, 4 µg/ml SBTI-1, 1 µg/ml 
leupeptin, 1% NP40, and 0.25% Na-deoxycholate.  Adherent cells were then harvested from 
the culture dishes with a cell scraper and transferred to chilled eppendorfs tubes. Whole cell 
lysates were centrifuged at 4°C and 8000 rpm for 10 minutes. Lysates were then stored at -
80°C and had their protein content determined the following day. Protein content was 
quantified using the Bradford protein determination method (Bradford. 1976), after the 
preparation of cell lysates. A complete step by step protocol for protein extraction and 
protein quantification by the Bradford method is included in Appendix A (p 113). 
3.4.4.2 Sample preparation 
Following protein quantification, aliquots containing 20 µg of protein were prepared for 
each sample. Lysates were diluted in Laemmli sample buffer, boiled for 5 minutes and then 
centrifuged for 5 seconds. Laemmli sample buffer consists of 150 μl mercaptoethanol and 
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850 μl of a sample buffer containing: 0.5 M Tris, pH 6.8, 10% SDS, 2.5 ml glycerol, 0.2 ml 
0.5% bromophenol blue and distilled water. The prepared samples were stored at -80°C for 
future analysis by Western blotting. A complete step by step protocol for sample 
preparation is included in Appendix A.  
3.4.4.3 SDS-PAGE and Western blot analysis 
The prepared cell lysates were separated on 10% polyacrylamide gels by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). For the determination of the 
molecular weights of specific bands 7.5 μl of a protein marker ladder (peqGold) was loaded 
in the left most well of each gel. This was also done for orientation purposes. Samples, 
previously prepared, were boiled for 5 minutes before 20 µg of protein was loaded into each 
well. Gels ran for an initial 10 minute run at 100 V and 400 mA, followed by 50 minutes at 
200 V and 400 mA (Mini Protean System, Bio-Rad, Hercules). Following SDS-PAGE, proteins 
were transferred to polyvinylidene fluoride (PVDF) membranes (Immoblin-P, Millipore) using 
a semi-dry electrotransfer system (Bio-Rad, USA) for 60 min at 15 V and 0.5 A. Membranes 
were blocked in 5% (w/v) fat-free milk in 0.1% Tris Buffered Saline-Tween20 (TBS-T) for 1 
hour at room temperature with gentle agitation, in order to prevent non-specific binding. 
Membranes were then incubated overnight at 4°C with specific primary antibodies against 
caspase 3 (Cell Signalling, MA, USA) and cleaved PARP (Cell Signalling, MA, USA) (Table 2) 
diluted in TBS-T (1:1000). On the next day, membranes were washed 3 times in TBS-T with 
each wash lasting 5 minutes. After washing, membranes were incubated in anti-rabbit 
horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences, UK, and Dako 
Cytomation, Denmark) for 1 hour at room temperature with gentle agitation. Following the 
incubation period, membranes were washed a further three times in TBS-T with each wash 
lasting 5 minutes. Antibodies were detected using the ECL detection Kit (Bio Vision Inc.) and 
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bands were exposed to CL-Xposure (Thermo Scientific) X-ray film.  Following exposure the 
membranes were washed 3 times with distilled H2O and stripped by washing with 0.2 M 
NaOH followed by another wash with distilled H2O. Each wash lasted 5 minutes. Stripped 
membranes were blocked in 5% (w/v) fat-free milk in 0.1% TBS-T for 1 hour at room 
temperature with gentle agitation, in order to prevent non-specific binding. Membranes 
were then incubated overnight at 4°C with a specific primary antibody against β-actin (Cell 
Signalling, MA, USA) diluted in TBS-T (1:1000). On the next day the same procedure for 
secondary antibody incubation and band exposure was followed as previously mentioned. 
Exposed bands were quantified by densitometry using the UN-SCAN-IT© densitometry 
software (Silk Scientific Corporation, Utah, USA). Bands were expressed as optical density 
readings relative to the untreated control present on the same blot. A complete step by step 
protocol for SDS-PAGE and Western blot analysis is included in Appendix A (115). 
 
Table 2: Antibodies used in Western blot analysis and the thickness of the polyacrylamide gel 
that was used. 
Antibody Size (kD) Gel thickness 
caspase 3 35 kD 1 mm 
cleaved PARP 89 kD 1 mm 
3.5 Determination of MKP-1 expression 
The protocol for the Western blot analysis performed in this section is described in the materials 
and methods section (section 3.4.4, p 37). 100 000 MDA-MB231 cells were plated into 6-well cell 
culture plates prior to treatment. For the groups that needed transfection, the cells were 
reverse transfected during plating (Section 3.3.2, p 33). To determine the level of MKP-1 
inhibition and induction, membranes were incubated overnight at 4°C with a specific 
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primary antibody against MKP-1 (Santa Cruz Biotechnology, CA, USA) (Table 3) diluted in TBS-T 
(1:1 000). 
 
Table 3: Antibodies used in Western blot analysis and the thickness of the polyacrylamide gel 
that was used. 
Antibody Size (kD) Gel thickness 
MKP-1 40 kD 1 mm 
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3.6 Determination of autophagic induction 
3.6.1 Flow cytometry 
This technique was used to analyse the degree of autophagic induction in MDA-MB231 cells 
by staining with LysoTracker™red (Invitrogen™, USA). MDA-MB231 cells were randomly 
divided into groups and seeded in 6-well cell culture plates (Greiner Bio One) at a seeding 
density of 100 000 cells per well. For the groups that needed transfection, the cells were 
reverse transfected during plating (Section 3.3.2, p 33). The cells were left to plate and grow 
in 2 ml growth medium per well and the experimental plan set out in Figure 3.3 was 
followed. Growth medium for all groups were changed and replaced with fresh growth 
medium before the indicated treatment (Section 3.3.1, p 32) (Figure 3.3, p 34) started. The 
treatment was administered straight into the medium at the correct concentration. 
Following completion of the treatment protocol as described in section 3.3.1, the medium 
was drained and the cell monolayer was rinsed with warm sterile PBS. The medium from 
each well was drained into ten sterile 15 ml Falcon tubes (Greiner Bio One), labelled 
according to treatment. Cells were trypsinized for approximately 3 minutes or until they 
detached from the surface of the flask and each cell suspension was added to the 
appropriate 15 ml Falcon tube and centrifuged for 3 minutes at 1500 rpm. The supernatant 
was discarded and each pellet was re-suspended in 0.5 ml LysoTracker™red (Invitrogen™, 
USA) working solution (final concentration of 100 nmol/L made up in growth medium). The 
suspension was incubated for 15 minutes at 37°C and gently re-suspended before being 
filtered through a 50 μm nylon mesh into FACS tubes and analysed immediately on the flow 
cytometer. Analyses were performed on a FACSAria I flow cytometer (Becton Dickinson 
Biosciences, San Jose, CA) equipped with a 488 nm Coherent Sapphire solid state laser (13-
20 mW), 633 nm JDS Uniphase HeNe air-cooled laser (10-20 mW) and 407 nm Point Source 
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Violet solid state laser (10-25 mW). For each sample, population information from a 
minimum of 10 000 events was acquired using FACSDiva Version 6.1 software. Data was 
expressed in arbitrary values as a percentage relative to the untreated control. A complete 
step by step protocol for flow cytometry is reproduced in Appendix A (p 110).  
3.6.2  LysoTracker™Stain 
LysoTracker™(Invitrogen™, USA) is a common stain that is used to detect autophagy. It stains 
autophagic vacuoles – double membrane structures that are produced in the cytoplasm – 
and on contact with LysoTracker™it emits a red fluorescence. This method is a way of 
quantitatively confirming results obtained in flow cytometry with LysoTracker™™. MDA-
MB231 cells were randomly divided into groups and seeded in 8-well chambers (Greiner Bio 
One) at a seeding density of 3000 cells per well. For the groups that needed transfection, the 
cells were reverse transfected during plating (Section 3.3.2, p 33). The cells were left to plate 
and grow in 200 µl growth medium per well and the experimental plan set out in Figure 3.3 
was followed. Growth medium for all groups were changed and replaced with fresh growth 
medium before the indicated treatment (Section 3.3.1, p 32) (Figure 3.3) started. The 
treatment was administered straight into the medium at the correct concentration. After 
treatment of the groups as described in section 3.3.1, the medium was drained and the cell 
monolayer was washed three times with warm sterile PBS. LysoTracker™red (1 µl in 2 ml 
medium) (Invitrogen™, USA) was made up in growth medium and 200 µl growth medium/ 
LysoTracker™solution was added to each well which covered the entire monolayer. The cells 
were left to incubate for 5 minutes. Images were acquired directly after the incubation 
period using an Olympus Cell^R system attached to an IX-81 inverted fluorescence 
microscope equipped with an F-view-II cooled CCD camera (Soft Imaging Systems). Using a 
Xenon-Arc burner (Olympus Biosystems GMBH) as light source, images were excited with the 
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572 nm excitation filter. Emission was collected using a UBG triple band pass emission filter 
cube. Images were processed and background subtracted using the Cell® software. Images 
were taken of a minimum of three randomly chosen fields, of at least three independent 
experiments per treatment group and the degree of autophagy was detected by means of 
red stained autophagic vacuoles. A complete step by step protocol for LysoTracker™staining 
is reproduced in Appendix A (p 109). 
3.6.3   Western blot analysis of LC3 and p62 
The protocol for the Western blot analysis performed in this section is described in Section 3.4.4 
(p 37) of the Materials and Methods. 100 000 MDA-MB231 cells were plated into 6-well cell 
culture plates prior to treatment. For the groups that needed transfection, the cells were 
reverse transfected during plating (Section 3.3.2, p 33). For the determination of autophagic 
induction, membranes were incubated overnight at 4°C with specific primary antibodies 
against LC3 (Cell Signalling, MA, USA) and p62 (Cell Signalling, MA, USA) (Table 4) diluted in 
TBS-T (1:1 000). 
 
Table 4: Antibodies used in Western blot analysis and the thickness of the polyacrylamide gel 
that was used. 
Antibody Size (kD) Gel thickness 
LC-3 17 kD 1 mm 
p62 1 62 kD 1 mm 
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 MKP-1 
 
 Western blot – MKP-1 
 
 Western blot – LC3, p62 
 Autophagy  Apoptosis 
  Western blot – Caspase 3 
Doxorubicin (5 mg/kg) 
Sanguinarine (0.22 mg/kg) 
+ Doxorubicin (5 mg/kg) 
3.7 In-vivo mouse model 
3.7.1 Study design 
 
Sanguinarine (0.22 mg/kg) 
Figure 3.4: Study design: Eight week-old female C57BL6 mice were inoculated with 2.5x105 E0771 cells. Tumours were left to 
grow for 3 weeks before intervention started. Mice were treated with doxorubicin and an MKP-1 inhibitor, sanguinarine. 
Autophagy and apoptosis was detected by means of western blotting. MKP-1 expression was also detected by western blot. 
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3.7.2 Experimental protocol 
This mouse model was established by a member of our Research group and the protocol was 
adapted from Ewens et al. 2006. The protocols in this study were carried out according to the 
guidelines for the care and use of laboratory animals implemented at Stellenbosch University. 
Eight week-old female C57BL6 mice (Stellenbosch University animal facility) were used in this 
study. Mice were inoculated subcutaneously with 2.5x105 E0771 cells suspended in 200 µl Hanks 
balanced salt solution (Sigma Chemical Co., St Louis, MO, USA) on the left pad of the fourth 
mammary gland, using a 23-gauge needle (Figure 3.6).  The E0771 cell line is a murine metastatic 
mammary adenocarcinoma cell line and was generously provided by Fengzhi Li (Roswell Park 
Cancer Institute, Buffalo, New York, USA). The experimental plan set out in Figure 3.5 was 
followed.  
 
 
 
  
First appearance 
of tumours 
Day 14 Day 21 Day 35 Day 0 
Tumour cell 
inoculation 
Tumour 
harvesting 
Treatment 
Figure 3.5: Experimental plan for in vivo study. Mice were injected with E0771 breast tumour cells on day 0. 
Tumours started to appear on day 14 after inoculation and doxorubicin and sanguinarine treatment started 
on day 21. Treatment was given over a course of 14 days after which the mice were sacrificed and the 
tumours harvested on day 35.  
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3.7.3 Treatment  
Intervention consisted of 4 intraperitoneal injections of doxorubicin (5 mg/kg) and sanguinarine 
(0.22 mg/kg) dissolved in Hanks balanced salt solution (Sigma Chemical Co., St Louis, MO, USA) 
given over a course of 14 days. Tumour size was monitored immediately before each treatment 
injection by making measurements in two perpendicular dimensions parallel with the surface of 
the mice using digital callipers. The body weight of the mice was monitored at the same time. 
Mice were sacrificed on day 35 and whole excised tumours were snap-frozen in liquid nitrogen 
and then stored at -80°C.  
 
A B 
Figure 3.6: 200 µl E0771 cell suspension was injected subcutaneously into mammary fat pad no.4. (A) 
Illustration portraying positions of mammary fat pads 4, 5, 10 and 9. (B) Subcutaneous injection with 
E0771 cell suspension. Protocol adapted from Ewens et al. 2006. 
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3.7.4 Western blot analyses of autophagy, apoptosis and MKP-1 
3.7.4.1 Protein extraction and quantification 
Frozen samples were allowed to thaw and homogenized in modified RIPA buffer (Appendix A, p 
110) on ice before being centrifuged at 4°C and 8 000 rpm for 10 minutes. The protein content 
was determined using the Bradford protein determination method (Bradford. 1976), after 
the preparation of lysates. A complete step by step protocol for protein extraction and 
protein quantification by the Bradford method is included in Appendix A (p 113).  
3.7.4.2 Sample preparation 
Following protein quantification, aliquots containing 20 µg of protein were prepared for 
each sample. Lysates were diluted in Llaemmli sample buffer, boiled for 5 minutes and then 
centrifuged for 5 seconds. Llaemmli sample buffer consists of 150 μl mercaptoethanol and 
850 μl of a sample buffer containing: Tris 0.5 M, pH 6.8, 10% SDS, 2.5 ml glycerol, 0.2 ml 
0.5% bromophenol blue and distilled water.  
3.7.4.3 SDS-PAGE and Western blot analysis 
The protocol for the Western blot analysis set out in section 3.4.4 (p 37) of Materials and 
Methods was performed and membranes were incubated overnight at 4°C with specific 
primary antibodies against caspase 3 (Cell Signalling, MA, USA), cleaved PARP (Cell Signalling, 
MA, USA), MKP-1 (Santa Cruz Biotechnology, CA, USA), LC-3 (Cell Signalling, MA, USA), p62 (Cell 
Signalling, MA, USA) and β-actin (Cell Signalling, MA, USA) diluted in TBS-T (1:1000). 
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3.8 Statistical analysis 
Controls were normalized and all values were expressed as a percentage of the untreated 
control. Results are presented as mean ± Standard Error of the Mean (SEM). Comparisons 
between different groups were made by one-way analysis of variance (ANOVA), followed by 
the Bonferroni post-hoc test. Statistical analyses were performed using Graphpad Prism 
version 5.01 (Graphpad Software, Inc, CA, USA) and a value of p < 0.05 was considered 
statistically significant. 
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Chapter 4: 
Results 
4.1 Determination of cell death 
The first aim of the research was to determine whether MKP-1 inhibition can sensitise breast 
cancer cells to doxorubicin treatment. To determine the effect of MKP-1 induction and 
inhibition in combination with doxorubicin treatment on cell death in MDA-MB231 cells, 
four techniques were employed. a) Trypan blue assay, b) Caspase-Glo® 3/7 assay, c) Western 
blots and d) Hoechst 33342 staining technique (Fluorescence microscopy). Three 
independent experiments were carried out for accuracy and repeatability. 
4.1.1 Trypan blue assay 
Based on an initial dose response experiment, 5 µM doxorobucin treatment for 24 hours 
showed a significant (p < 0.05) decrease in cell death compared to the control. 
 
Figure 4.1: The effect of treatment with doxorubucin on cell death induction in MDA-MB231 cells. MDA-MB231 cells were 
seeded at a high seeding density and treated with doxorubicin at different concentrations over time. Cells were stained 
with Trypan blue, viable and non-viable cells were counted using a haemocytometer. Results are presented as means ± SEM 
(n=3). * p < 0.05 vs control 
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To assess the viability of MDA-MB231 cells after a 24 hour treatment period, the trypan blue 
exclusion assay was used. The assay is based on the principal that viable cells will be able to 
exclude the blue dye from entering the cell, whilst non-viable cells are unable to prevent its 
entrance into the cytoplasm. Doxorubicin treatment showed a highly significant (p < 0.001) 
decrease in cell viability compared to the control group (Figure 4.2). Dexamethasone 
treatment alone had no effect with no significant decrease in cell viability compared to the 
control group.  
There was a significant (p < 0.001) increase in cell viability in the cells treated with 
dexamethasone in combination with doxorubicin when compared to doxorubicin treatment 
alone.  
 
Figure 4.2: The effect of treatment with dexamethasone in conjunction with doxorubicin on cell death induction in MDA-
MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with dexamethasone (100 nM) and 
doxorubicin (5 µM) for 24 hours. Cells were stained with trypan blue, viable and non-viable cells were counted using a 
haemocytometer. Results are presented as means ± SEM (n=3). *** p < 0.001 vs control, 
###
 p < 0.001 vs doxorubicin 
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Treatment with Doxorubicin alone decreased cell viability significantly (p < 0.001) in MDA-
MB231 cells. Sanguinarine treatment only showed a small insignificant decrease in cell 
viability compared to the control group (Figure 4.3). A statistically significant decrease in cell 
viability was also observed during treatment with Doxorubicin under conditions of MKP-1 
inhibition. Here a significant (p < 0.001) decrease in cell viability was observed in the group 
treated with doxorubicin in combination with sanguinarine when compared to doxorubicin 
treatment alone. 
 
Figure 4.3: The effect of treatment with sanguinarine in conjunction with doxorubicin on cell death induction in MDA-MB231 
cells. MDA-MB231 cells were seeded at a high seeding density and treated with sanguinarine (0.5 µM) and doxorubicin (5 
µM) for 24 hours. Cells were stained with trypan blue and viable and non-viable cells were counted using a 
haemocytometer. Results are presented as means ± SEM (n=3). *** p < 0.001 vs control, 
###
 p < 0.001 vs doxorubicin 
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5 µM Doxorubicin treatment significantly (p < 0.001) reduced cell viability compared to the 
control. Treatment with MKP-1 siRNA revealed no significant decrease in cell viablity when 
compared to the control (Figure 4.4). A significant (p < 0.01) decrease in cell viablity was 
observed with doxorubicin treatment in conjunction with MKP-1 siRNA compared to 
doxorubicin treatment alone.  
 
Figure 4.4: The effect of MKP-1 siRNA in conjunction with doxorubicin on cell death induction in MDA-MB231 cells. MDA-
MB231 cells were seeded at a high seeding density, MKP-1 was silenced via reverse transcription and cells were treated 
with doxorubicin (5 µM) for 24 hours. Cells were stained with trypan blue and viable and non-viable cells were counted 
using a haemocytometer. Results are presented as means ± SEM (n=3). *** p < 0.001 vs control, 
##
 p < 0.01 vs doxorubicin 
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4.1.2 Caspase 3/7 activity assay 
The Caspase-Glo® 3/7 assay was used to determine the caspase 3/7 activity in MDA-MB231 
cells following treatment. This assay is luminescent assay that provides an extremely 
sensitive means of monitoring caspase 3/7 activation. Following treatment with 5 µM 
doxorubicin, a significant (p < 0.001) increase in caspase 3/7 cleavage was observed 
compared to the control (Figure 4.5). Dexamethasone and vehicle treatments had no effect 
on caspase 3/7 cleavage compared to the control. 
 
 
Figure 4.5: The effect of treatment with dexamethasone in conjunction with doxorubicin on caspase 3/7 activity in MDA-
MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with dexamethasone (100 nM) and 
doxorubicin (5 µM) for 24 hours. The caspase 3/7 activity was measured using the Caspase-Glo® 3/7 assay. Results are 
presented as means ± SEM (n=4). *** p < 0.001 vs control 
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Doxorubicin treatment significantly (p < 0.001) increased caspase 3/7 cleavage. Sanguinarine 
treatment alone had no effect on caspase 3/7 cleavage compared to the control (Figure 4.6). 
Under conditions of MKP-1 inhibition in combination with doxorubicin treatment there was 
an increase in caspase 3/7 activity. This was seen in the cells treated with doxorubicin in 
combination with sanguinarine where a significant (p < 0.001) increase in caspase 3/7 
cleavage was found compared to doxorubicin treatment alone. 
 
 
Figure 4.6: The effect of sanguinarine in conjunction with doxorubicin on caspase 3/7 activity in MDA-MB231 cells. MDA-
MB231 cells were seeded at a high seeding density and treated with sanguinarine (0.5 µM) and doxorubicin (5 µM) for 24 
hours. The caspase-3/7 activity was measured using the Caspase-Glo® 3/7 assay. Results are presented as means ± SEM 
(n=4). *** p < 0.001 vs control, 
###
 p < 0.001 vs doxorubicin 
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MKP-1 siRNA had little effect on caspase 3/7 cleavage with no significant increase compared 
to the control (Figure 4.7). Negative siRNA had no significant effect on caspase 3/7 cleavage 
compared to the control. 
 
  
Figure 4.7: The effect of MKP-1 siRNA in conjunction with doxorubicin on the caspase 3/7 activity in MDA-MB231 cells. 
MDA-MB231 cells were seeded at a high seeding density, MKP-1 was silenced via reverse transcription and cells were 
treated with doxorubicin (5 µM) for 24 hours. The caspase-3/7 activity was measured using the Caspase-Glo® 3/7 assay. 
Results are presented as means ± SEM (n=4). *** p < 0.001 vs control 
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4.1.3 Western blot analysis 
4.1.3.1 Total caspase 3 
Caspase-3 is activated by both the intrinsic and extrinsic pathway in an apoptotic cell. Being 
an executioner caspase, it has no activity until it is cleaved and thereby activated by initiator 
caspases upon apoptotic signalling. Apoptotic activity was investigated in MDA-MB231 cells 
using Western blotting and probing for caspase 3.  
Doxorubicin treatment presented with a significant (p < 0.001) decrease in total caspase 3 
levels compared to the control (Figure 4.8). Furthermore, significance was noted under 
conditions of MKP-1 inhibition in combination with doxorubicin treatment. Here a significant 
(p < 0.001) decrease in total caspase 3 was seen in groups treated with sanguinarine and 
MKP-1 siRNA in combination with doxorobicin treatment compared to doxorubicin 
treatment alone.  
During dexamethasone treatment in combination with doxorubicin a decrease in caspase 3 
was also observed. This decrease was however significantly (p < 0.01) higher compared to 
doxorubicin treatment alone. Dexamethasone (p < 0.01) and MKP-1 siRNA (p < 0.05) 
significantly increased caspase 3 expression compared to the control. Sanguinarine 
treatment showed no significant increase in caspase 3 compared to the control. 
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Figure 4.8: The effect of 24 hour doxorubicin treatment together with MKP-1 inhibitors and inducers on caspase 3 expression 
in MDA-MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with dexamethasone (100 nM), 
doxorubicin (5 µM) and sanguinarine (0.5 µM) for 24 hours. MKP-1 was silenced via reverse transfection. Results are 
presented as means ± SEM (n=3). * p < 0.05 vs control, ** p < 0.01 vs control, *** p < 0.001 vs control, 
## 
p < 0.01 vs 
doxorubicin, 
###
 p < 0.001 vs doxorubicin 
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4.1.3.2 Cleaved PARP 
To confirm the results obtained from caspase 3 western blots, the membranes were also 
probed for cleaved PARP. Following treatment, PARP cleavage increased significantly (p < 
0.001) in MDA-MB231 cells treated with doxorubicin compared to the control (Figure 4.9). 
Treatment with doxorubicin in the presence of MKP-1 inhibition showed a substantial 
increase in PARP cleavage. Here the cells treated with doxorubicin in combination with MKP-
1 siRNA revealed a significant (p < 0.001) increase in PARP cleavage compared to the control. 
The combination of MKP-1 induction (dexamethasone) together with doxorubicin treatment 
also increased PARP cleavage. The increase in PARP cleavage in the cells treated with 
dexamethasone in conjunction with doxorubicin was however less compared to both 
doxorubicin treatment and treatment with MKP-1 siRNA in conjunction with doxorubicin 
treatment.  
The combination of sanguinarine and doxorubicin also increased PARP cleavage compared to 
the control, but PARP cleavage was significantly (p < 0.05) reduced compared to doxorubicin 
treatment. Dexamethasone, sanguinarine, MKP-1 siRNA, negative siRNA and vehicle treated 
groups had no significant effect on PARP cleavage compared to the control. 
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Figure 4.9: The effect of 24 hour doxorubicin treatment together with MKP-1 inhibitors and inducers on cleaved PARP 
expression in MDA-MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with dexamethasone 
(100 nM), doxorubicin (5 µM) and sanguinarine (0.5 µM) for 24 hours. MKP-1 was silenced via reverse transfection. Results 
are presented as means ± SEM (n=3). *** p < 0.001 vs control, 
#
 p < 0.05 vs doxorubicin 
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4.2 LysoTracker™ and Hoechst 33342 stain 
To qualitatively assess the effect of MKP-1 inhibition on the lysosomal compartment and cell 
death, we investigated morphological changes that signify apoptosis as well as the volume of 
the acidic compartment by staining MDA-MB231 cells with Hoechst 33342 and LysoTracker™ 
red respectively. Images taken revealed an increase in the size and number of acidic vesicles 
in response to sanguinarine or MKP-1 siRNA therapy as well as in cells treated with both 
sanguinarine and doxorubicin or MKP-1 siRNA and doxorubicin (Figure 4.10). An increase in 
cell death (pyknosis and apoptotic bodies) was also observed in the groups treated with 
dexamethasone and doxorubicin or MKP-1 siRNA and doxorubicin and the highest degree of 
cell death was seen in the cells treated with sanguinarine in combination with doxorubicin. 
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Figure 4.10: The effect of 24 hour doxorubicin treatment together with MKP-1 inhibitors and inducers on autophagy and 
apoptosis in MDA-MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with dexamethasone 
(100 nM), doxorubicin (5 µM) and sanguinarine (0.5 µM) for 24 hours. MKP-1 was silenced via reverse transfection. MDA-
MB231 cells were stained with Hoechst 33342 (blue) and LysoTracker™ red (red) and apoptosis and autophagy was 
scrutinized using fluorescence microscopy. The arrow indicates an apoptotic body (blue) and autophagic vacuoles (red).
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4.3 MKP-1 expression in MDA-MB231 cells 
MKP-1 expression was examined in MDA-MB231 cells by means of western blotting. 100 nM 
Dexamethasone treatment significantly (p < 0.01) increased MKP-1 expression in MDA-
MB231 cells compared to the control (Figure 4.11). A significant decrease in MKP-1 
expression was observed when MDA-MB231 cells were treated with 0.5 µM sanguinarine (p 
< 0.001) and MKP-1 siRNA (p < 0.05) compared to the control. A significant (p < 0.001) 
decrease in MKP-1 was also observed with combined sanguinarine and doxorubicin 
treatment when compared to the control. 
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Figure 4.11: The effect of 24 hour doxorubicin treatment together with MKP-1 inhibitors and inducers on MKP-1 expression in 
MDA-MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with dexamethasone (100 nM), 
doxorubicin (5 µM) and sanguinarine (0.5 µM) for 24 hours. MKP-1 was silenced via reverse transfection. Results are 
presented as means ± SEM (n=3). * p < 0.05 vs control, ** p < 0.01 vs control, *** p < 0.001 vs control 
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4.4 Determination of autophagic induction in MDA-MB231 cells 
The first aim of this research was to determine whether MKP-1 inhibition can sensitize 
breast cancer cells to doxorubicin treatment. The second aim was to determine the role of 
autophagy in this scenario in MDA-MB231 cells. Three techniques were used; flow 
cytometry, western blotting and LysoTracker™red staining (fluorescence microscopy). Three 
independent experiments were conducted for accuracy and reproducibility. 
4.4.1 Flow cytometry 
To assess the degree of autophagy induction in MDA-MB231 cells following treatment, cells 
were stained with LysoTracker™ red, and the mean fluorescence intensity was analysed 
using flow cytometry. Treatment with 5 µM doxorubicin significantly (p < 0.05) increased 
autophagy compared to the control (Figure 4.12). Dexamethasone treatment, a known MKP-
1 inducer, had no effect with a negligible increase in autophagy induction compared to the 
control. The combination of dexamethasone and doxorubicin also showed a significant (p < 
0.05) increase in autophagy induction compared to the control; however this had the same 
effect as doxorubicin treatment alone. 
 
 
 
 
 
 
 
 
 
Figure 4.12: The effect of treatment with dexamethasone in conjunction with doxorubicin on the degree of autophagic 
induction in MDA-MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with dexamethasone 
(100 nM) and doxorubicin (5 µM) for 24 hours. Cells were stained with LysoTracker™red, and the mean fluorescence 
intensity was determined by flow cytometry. Results are presented as means ± SEM (n=3). *p < 0.05 vs control 
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Treatment with doxorubicin alone significantly (p < 0.05) increased autophagic induction in 
MDA-MB231 cells. Sanguinarine treatment also showed an increase in autophagy but this 
increase was less compared to doxorubicin therapy alone and not statistically significant 
(Figure 4.13). An increase in autophagy was also observed during treatment with 
doxorubicin under conditions of MKP-1 inhibition. The substantial increase in autophagy 
observed in the group treated with doxorubicin in combination with sanguinarine when 
compared to both the control and doxorubicin treatment alone was however not statistically 
significant. 
 
Figure 4.13: The effect of sanguinarine in conjunction with doxorubicin on the degree of auotphagic induction in MDA-
MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with sanguinarine (0.5 µM) and 
doxorubicin (5 µM) for 24 hours. Cells were stained with LysoTracker™red and the mean fluorescence intensity was 
determined by flow cytometry. Results are presented as means ± SEM (n=3). *p < 0.05 vs control 
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Treatment with MKP-1 siRNA showed no significant increase in autophagy induction 
compared to the control (Figure 4.14). A significant (p < 0.05) increase in autophagic 
induction was observed with doxorubicin treatment in conjunction with MKP-1 siRNA, 
however, this effect was similar as with doxorubicin treatment alone. 
 
 
 
 
 
 
Figure 4.14: The effect MKP-1 siRNA in conjunction with doxorubicin on the degree of auotphagic induction in MDA-MB231 
cells. A) MDA-MB231 cells were seeded at a high seeding density, MKP-1 was silenced via reverse transcription and cells 
were treated with doxorubicin (5 µM) for 24 hours. Cells were stained with LysoTracker™red and the mean fluorescence 
intensity was determined by flow cytometry. B) The scatterplot indicates how the gating was done and P2 shows the shift in 
doxorubicin treated cells. Results are presented as means ± SEM (n=3). *p < 0.05 vs control 
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4.4.2 Western blot analysis 
4.4.2.1 LC3 
LC3 is used as one of the most common markers of autophagy. The conversion of LC3 I to 
LC3 II indicates increased autophagy activity in a cell.  
Following treatment, elevated LC3 II expression was an indicator of increased autophagy in 
MDA-MB231 cells. LC3 II expression increased in all the treatment groups, except for siRNA 
and vehicle, when compared to the control (Figure 4.15). A significant (p < 0.01) increase in 
LC3 II expression was observed under conditions of MKP-1 inhibition where the cells were 
treated with doxorubicin in combination with sanguinarine.  
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Figure 4.15: The effect of 24 hour doxorubicin treatment together with MKP-1 inhibitors and inducers on LC3 II expression in 
MDA-MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with dexamethasone (100 nM), 
doxorubicin (5 µM) and sanguinarine (0.5 µM) for 24 hours. MKP-1 was silenced via reverse transfection. Results are 
presented as their means ± SEM (n=3). 
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 p < 0.01 vs doxorubicin. 
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4.4.2.2 p62 
Another common marker of autophagy, p62, was used to confirm the results obtained from 
LC3 western blots. p62 is present in the autophagolysosome and its expression is decreased 
during high autophagic activity due to recycling.  
Following treatment, decreased p62 expression was evident of increased autophagy in MDA-
MB231 cells.  Doxorubicin therapy decreased p62 expression compared to the control 
(Figure 4.16). Also, p62 expression was even further decreased under conditions of MKP-1 
inhibition in combination with doxorubicin treatment. This was evident in the groups treated 
with sanguinarine in conjunction with doxorubicin and siRNA in conjunction with 
doxorubicin. The lowest p62 expression was observed in the cells treated with sanguinarine 
in combination with doxorubicin when compared to doxorubicin treatment alone. Although 
a trend was noticed these findings was not significant.  
p62 was significantly increased in dexamethasone (p < 0.001) and sanguinarine (p < 0.01) 
treated groups compared to the control. MKP-1 siRNA treatment showed no significant 
changes compared to the control. Under conditions of MKP-1 induction in combination with 
doxorubicin treatment there was also an increase in p62 expression. This was evident in the 
cells treated with dexamethasone in combination with doxorubicin and the increase was 
larger compared to doxorubicin treatment alone, however it was not significant. 
 
Stellenbosch University  http://scholar.sun.ac.za
 69 
 
 
 
  
0
0.5
1
1.5
2
2.5
3
3.5
4
P
6
2
 
Fo
ld
 in
cr
e
as
e
 
*** 
** 
β-actin 
Figure 4.16: The effect of 24 hour doxorubicin treatment together with MKP-1 inhibitors and inducers on p62 expression in 
MDA-MB231 cells. MDA-MB231 cells were seeded at a high seeding density and treated with dexamethasone (100 nM), 
doxorubicin (5 µM) and sanguinarine (0.5 µM) for 24 hours. MKP-1 was silenced via reverse transfection. Results are 
presented as means ± SEM (n=3). ** p < 0.01 vs control, *** p < 0.001 vs control 
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4.5 In-vivo Study 
4.5.1 Tumour growth 
Tumour volume increased over time for all treatment groups.  
 
 
Figure 4.17: Change in tumour volume of C57BL6 mice injected with E0771 murine mammary cancer cells at day 0 (n=4). 
Arrows indicate days when animals were treated. 
 
 
 
 
 
 
 
 
 
0
50
100
150
200
250
300
350
1 21 26 30 35
Tu
m
o
u
r 
vo
lu
m
e
 (
m
m
2
) 
Days after injection 
Control
Doxorubicin
Sanguinarine
Sang + Dox
Stellenbosch University  http://scholar.sun.ac.za
 71 
4.5.2 Western blot analysis 
4.5.2.1 Total Caspase 3  
Total caspase 3 levels decreased in the tumours of mice treated with doxorubicin in 
combination with sanguinarine (p < 0.05) compared to the control (Figure 4.18). This echoed 
previous findings (Section 2.3.1) where caspase 3 was found to be decreased in MDA-MB231 
cells when treated with doxorubicin under conditions of MKP-1 inhibition.  
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Figure 4.18: The effect of doxorubicin treatment together with MKP-1 inhibitor, sanguinarine, on caspase 3 expression in 
tumour bearing mice. Mice were inoculated with doxorubicin (5 mg/kg) and sanguinarine (0.22 mg/kg). Results are 
presented as means ± SEM (n=3). * p < 0.05 vs control 
 
Stellenbosch University  http://scholar.sun.ac.za
 72 
4.5.2.2 MKP-1 
MKP-1 expression was significantly (p < 0.001) decreased in all treated groups compared to 
the control (Figure 4.19). These findings correlate, once again with the findings from the in-
vitro study. 
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Figure 4.19: The effect of doxorubicin treatment together with MKP-1 inhibitor, sanguinarine, on MKP-1 expression in tumour 
bearing mice. Mice were inoculated with doxorubicin (5 mg/kg) and sanguinarine (0.22 mg/kg). Results are presented as 
means ± SEM (n=2). *** p < 0.001 vs control 
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4.5.2.3 LC3 II 
Treatment with doxorubicin combined with sanguinarine showed a significant (p < 0.05) 
increase in LC3 II expression in tumour bearing mice compared to doxorubicin treatment 
alone (Figure 4.20). This correlates with the increase in LC3 II expression in MDA-MB231 cells 
following treatment with doxorubicin in combination with MKP-1 inhibition. Sanguinarine 
treatment alone presented with a decrease in LC3 II whereas no significant differences were 
observed in LC3II with doxorubicin treatment alone compared to the control.  
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Figure 4.20: The effect of doxorubicin treatment together with MKP-1 inhibitor, sanguinarine, on LC3 II expression in tumour 
bearing mice. Mice were inoculated with doxorubicin (5 mg/kg) and sanguinarine (0.22 mg/kg). Results are presented as 
means ± SEM (n=3). 
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4.5.2.4 p62 
P62 expression was non-significantly decreased in tumours treated with doxorubicin, and 
doxorubicin combined with sanguinarine compared to the control (Figure 4.21). The lowest 
p62 expression was seen in the tumours treated with doxorubicin in combination with MKP-
1 inhibition. Sanguinarine treatment showed a non-significant increase in p62. 
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Figure 4.21: The effect of doxorubicin treatment together with MKP-1 inhibitor, sanguinarine, on p62 expression in tumour 
bearing mice. Mice were inoculated with doxorubicin (5 mg/kg) and sanguinarine (0.22 mg/kg). Results are presented as 
means ± SEM (n=3). 
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Chapter 5: 
Discussion 
Cancer is an emerging health problem in South Africa, and with breast cancer being one of 
the leading causes of death in woman world wide, the need for novel effective therapeutic 
targets is evident.  Chemotherapeutic agents can be limited in their ability to induce cell 
death in certain instances due to chemoresistance. It is therefore essential to find 
therapeutic targets that can assist anticancer agents in eliciting the desired response.  In this 
study we evaluated the effect of MKP-1 inhibition on MDA-MB231 cells as well as in an in 
vivo mouse tumour model to investigate whether its inhibition together with doxorubicin 
treatment has an influence on autophagy levels and cell death in breast carcinoma cells.  
5.1 In vitro study 
5.1.1 Role of MKP-1 inhibition on cell viability 
The Trypan blue exclusion assay was used to assess the viability of MDA-MB231 cells 
following a 24 hour treatment period.  Cell viability was investigated in MDA-MB231 breast 
cancer cells treated with doxorubicin, a MKP-1 inducer (dexamethasone), and MKP-1 
inhibitors – sanguinarine and MKP-1 siRNA – as well as combinations of these compounds.  
In MDA-MB231 cells, 5 µM doxorubicin treatment significantly decreased cell viability after 
24 hour treatment (Figure 4.2). This was in line with previous observations where 
doxorubicin caused DNA damage following addition to cancer cells (Eom et al. 2005).  
No significant difference in cell viability was detected when cells were treated with 
dexamethasone alone compared to the control. This is in agreement with previous studies 
where it was shown that glucocorticoids protect mammary gland epithelial cells and 
hepatocytes as well as ovarian follicular cells against cell death signals (Redondo et al. 2007). 
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Dexamethasone induces MKP-1 via dimerization of the glucocorticoid receptor (Vandevyver 
et al. 2012). Interestingly, when the MDA-MB231 cells were treated with dexamethasone in 
conjunction with doxorubicin treatment, a significant increase in viability was observed 
compared to doxorubicin treatment alone (Figure 4.2).  
Pre-treatment with sanguinarine followed by doxorubicin caused a significant decrease in 
cell viability in MDA-MB231 cells when compared to the group treated with doxorubicin 
alone (Figure 4.3). This is a novel finding which can be supported by studies showing that 
MKP-1 inhibition induced apoptosis in Caski-1, KU 20-01 cells (Mizuno et al. 2004) and  rat 
mesangial cells (Xu et al. 2004). This finding suggests that sanguinarine therapy sensitized 
the MDA-MB231 cells to doxorubicin-induced-cell death. This is encouraging since this could 
be used in future studies looking to overcome doxorubicin resistance in breast cancer cells.  
Treatment with MKP-1 siRNA had no effect on cell viability (Figure 4.4). The addition of MKP-
1 siRNA with doxorubicin decreased cell viability significantly compared to doxorubicin 
therapy alone (Figure 4.4). This suggests that inhibiting MKP-1 together with doxorubicin 
therapy have a synergistic effect on decreasing cell viability in MDA-MB231 cells. 
5.1.2 The role of MKP-1 on apoptosis in MDA-MB231 cells 
To further substantiate the results obtained from the viability assay and to confirm the role 
of apoptosis in our cell model, the Caspase-Glo® 3/7 assay was done. This assay measures 
caspase 3/7 activity. Doxorubicin treatment caused a significant increase in caspase 3/7 
activity in MDA-MB231 cells (Figure 4.5). This is in agreement with results which have shown 
that doxorubicin induces apoptosis via the activation of caspases and the disruption of the 
mitochondrial membrane potential (Gamen et al. 2000). Dexamethasone treatment alone 
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had no effect on caspase 3/7 activity, which correlated with results from the Trypan blue 
assay (Figure 4.2). 
Sanguinarine treatment alone had no effect on caspase activity; however with the addition 
of doxorubicin to sanguinarine a significant increase in caspase 3/7 activity was observed 
compared to doxorubicin treatment alone (Figure 4.6).  Pre-treatment with sanguinarine 
followed by doxorubicin had a more pronounced effect on caspase 3/7 activity compared to 
MKP-1 siRNA and doxorubicin treatment. This finding correlates with data from the Trypan 
blue assay and even further substantiates the proposition that under conditions of MKP-1 
inhibition with sanguinarine, MDA-MB231 cells become sensitized to doxorubicin-induced-
apoptosis. 
MKP-1 siRNA alone had no effect on caspase 3/7 activity. MKP-1 siRNA in combination with 
doxorubicin also did not have an additive effect compared to doxorubicin treatment alone 
(Figure 4.7). This is in contrast with a study done in 2007 where MKP-1 siRNA together with 
cisplatin treatment increased cell death in OV433 ovarian cancer cells (Wang et al. 2007). 
This finding does not correlate with results obtained from the Trypan blue assay or the 
western blotting results where caspase 3 cleavage and PARP was measured. 
Western blot analysis indicated a significant decrease in uncleaved caspase 3 (Figure 4.8) 
with a subsequent significant increase in cleaved PARP (Figure 4.9) in MDA-MB231 cells 
treated with 5 µM doxorubicin. This finding confirmed the work of Gamen and co-workers 
who showed that doxorubicin-induced apoptosis in human T-cell leukaemia is mediated by 
caspase-3 activation (Gamen et al. 1997). Furthermore, in Jurkat cells, the doxorubicin 
induced caspase 3 activation was followed by PARP cleavage (Ferrari et al. 1998). Treatment 
with dexamethasone in combination with doxorubicin also showed a significant decrease in 
caspase 3 (Figure 4.8) followed by an increase in cleaved PARP (Figure 4.9). Interestingly, 
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uncleaved caspase 3 levels was significantly higher compared to the control group which 
confirmed the work of Redondo and co-workers who have demonstrated that 
glucocorticoids protect cancer cells against apoptosis (Redondo et al. 2007).  
Uncleaved caspase 3 was significantly decreased in MDA-MB231 cells treated with 
sanguinarine in combination with doxorubicin when compared to doxorubicin treatment 
alone. Interestingly, this was not mirrored in PARP cleavage where the addition of 
sanguinarine to doxorubicin caused an attenuation of PARP cleavage. This finding was 
unexpected and does not correlate with any previously mentioned findings. It is also in 
contrast with findings in human cervical cells (Ding et al. 2002), primary effusion lymphoma 
cells (Hussain et al. 2007) human leukaemia U937 cells (Han et al. 2008) and human colon 
cancer cells (Matkar et al. 2008) where sanguinarine-induced activation of caspase 3 was 
followed by PARP cleavage. An explanation for this might be the fact that PARP cleavage is a 
downstream event of caspase 3 cleavage. An increase might have been observed if the 
treatment period was extended. Furthermore, the above mentioned studies all used a high 
concentration (5 µM) of sanguinarine that had the ability to induce apoptosis on its own in 
various cell models; in our study sanguinarine was used as an MKP-1 inhibitor and 0.5 µM 
sanguinarine could inhibit MKP-1 without causing apoptosis on its own. MKP-1 siRNA 
combined with doxorubicin treatment also showed a significant decrease in uncleaved 
caspase 3 and increase in cleaved PARP. Our results corroborated that by Wang et al (2007) 
who showed that the inhibition of MKP-1, using MKP-1 siRNA, enhanced cisplatin-induced 
caspase 3 and PARP cleavage in OV433 ovarian cancer cells (Wang et al. 2007).  
Morphological changes, which are commonly associated with the progression of apoptosis, 
such as chromatin condensation and the formation of apoptotic bodies, were investigated in 
MDA-MB231 cells following the indicated treatment as previously described. Images taken 
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confirmed the results from the various cell death assays as an increase in cell death 
(pyknosis and apoptotic bodies) was observed in doxorubicin treated groups (Figure 4.10). 
The highest degree of cell death was observed in the cells pre-treated with sanguinarine 
followed by doxorubicin treatment. This further substantiates the notion that under 
conditions of MKP-1 inhibition, MDA-MB231 cells are sensitized to doxorubicin-induced 
apoptosis.  
5.1.3 MKP-1 expression in MDA-MB231 cells 
MKP-1 is a dual specificity phosphatase that is commonly associated with cancer progression 
and the resistance of cancer cells to chemotherapy. Hence, MKP-1 expression was 
investigated in MDA-MB231 breast cancer cells treated with doxorubicin, as well as with 
MKP-1 inducer (dexamethasone), and the MKP-1 inhibitors - sanguinarine and MKP-1 siRNA. 
Inducing MKP-1, using 100 nM dexamethasone, significantly increased MKP-1 expression in 
the MDA-MB231 cells (Figure 4.11). Several studies (Chen et al. 2002; Clark. 2003; Kassel et 
al. 2002; Lasa et al. 2002) demonstrated MKP-1 induction following dexamethasone 
treatment.  
Dexamethasone, a synthetic glucocorticoid, has significantly increased MKP-1 induction in 
our cell model compared with the control group. This is in agreement with the work of Lasa 
et al who has shown that MKP-1 expression is induced in HeLa cells following treatment with 
dexamethasone (Lasa et al. 2002). This increase in MKP-1 expression is mediated by the 
deactivation of p38 MAPK (Huang et al. 2011). 
MKP-1 was significantly inhibited following treatment with 0.5 µM sanguinarine and MKP-1 
siRNA. Moreover, MKP-1 siRNA was also shown to successfully inhibit MKP-1 expression in 
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MDA-MB231 cells (Wu et al. 2004). Sanguinarine is a bioactive plant extract that has been 
shown to effectively inhibit MKP-1 expression in PANC-1 and HeLa cells (Vogt et al. 2005).  
Doxorubicin treatment tended to decrease MKP-1 expression (Figure 4.11). Furthermore, 
MKP-1 expression was significantly reduced with sanguinarine pre-treatment in doxorubicin 
treated cells compared to the control. It has been reported that doxorubicin can deplete 
MKP-1 activity in rat pinealocytes (Price et al. 2007) as well as in A1N4-myc human 
mammary and BT-474 breast carcinoma cells, where the decrease in MKP-1 triggered 
enhanced JNK activation (Small et al. 2003).  
It has been suggested that the overexpression of MKP-1 in breast cancer inhibits the ability 
of alkylating agents, anthracyclines and taxanes to induce apoptosis in these cells. This 
overexpression is associated with decreased JNK activation (Small et al. 2007). Furthermore, 
when MKP-1 was supressed with siRNA, or targeted deletion, enhanced chemo sensitivity 
and increased JNK activity was observed (Small et al. 2007).  
5.1.4 The relation of MKP-1 with autophagy in MDA-MB231 cells 
Little is known about the role of MKP-1 in autophagy. We aimed to investigate whether 
MKP-1 inhibition might sensitize doxorubicin treated breast cancer cells to apoptosis 
through a mechanism involving autophagy. We therefore treated MDA-MB231 cells as 
previously described and evaluated autophagy levels with flow cytometry and western 
blotting.  
Results from both flow cytometry and western blots indicated an increase in autophagy with 
doxorubicin treatment. This was evident with a significant increase in LysoTracker™ 
fluorescence as well as a non-significant increase in LC3 II and decrease in p62 compared to 
the control (Figures 4.12 - 4.16). This can be supported by the fact that doxorubicin is known 
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to induce an autophagic response in cancer cells following treatment (Lambert et al. 2008; 
Manov et al. 2011). As expected, dexamethasone treatment had little effect on autophagy as 
evident in results from flow cytometry and both LC3 II and p62 western blots. LysoTracker™ 
fluorescence and LC3 II expression was slightly increased compared to the control. Although 
a significant increase in p62 was observed; it can be attributed to the fact that p62 is 
accumulating in the autophagolysosome and not being recycled due to a low autophagy flux.  
This finding does however not coincide with the literature where it has been shown that 
dexamethasone induced an autophagic response in lymphoid leukaemia cells (Laane et al. 
2009) and multiple myeloma cells (Grandér et al. 2009). Once again, discrepancies might be 
attributed to the concentration of dexamethasone used in these studies, as a concentration 
of 1 µM was used vs 100 nM used in our study. 
Inhibiting MKP-1 using sanguinarine and MKP-1 siRNA did not increase autophagy in MDA-
MB231 cells. This is evident from both flow cytometry (Figure 4.13 - 4.14) and western blot 
(Figure 4.15 – 4.16) results showing almost no change in LC3 II compared to the control and 
an increase in p62 following treatment. However, when MDA-MB231 cells were treated with 
doxorubicin in combination with MKP-1 inhibition, an increase in autophagy was observed. 
Sanguinarine pre-treatment showed the highest LysoTracker™ fluorescence compared to 
both dexamethasone and MKP-1 siRNA. This was however not significant, but it can be 
attributed to the large standard deviation between samples due to the flow cytometer being 
serviced between the initial and final experiment.  
The increase in autophagy in the cells treated with sanguinarine in combination with 
doxorubicin was also evident in the significant increase in LC3 II and decrease in p62 
expression. This novel finding demonstrates that the inhibition of MKP-1 together with 
doxorubicin treatment activate autophagy in our cell model. In contrast to our findings, 
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recent literature indicated that autophagy induction was associated with MKP-1 activation in 
oral cancer cells (Lu et al. 2010) as opposed to MKP-1 inhibition. Although no significance 
was evident in some of the results obtained from LC3 II and p62 western blots, clear 
difference was apparent in the blots, but due to a small sample size and large standard 
deviation these effects were blunted.  
Studies on the effect of MKP-1 inhibition in autophagy are limited and leave one to 
speculate whether JNK and p38 MAPK’s are involved in this scenario. A study done by Li et al 
(2009) showed that JNK activation in human cancer cell lines, CNE2 and Hep3B, mediated 
Beclin 1 expression which induced autophagy and subsequently resulted in cell death (Li et 
al. 2009).  
5.2 In vivo study 
5.2.1 The effect of MKP-1 inhibition on autophagy and apoptosis in 
tumour bearing mice 
In order to further substantiate the results obtained from the in vitro study an in vivo study 
was conducted. C57BL6 mice were inoculated with E0771 breast cancer cells and tumours 
were left to grow for 21 days before intervention started. Intervention consisted of four 5 
mg/kg doxorubicin or 0.22 mg/kg sanguinarine intraperitoneal injections or a combination of 
the two given over a course of 14 days after which the tumours were excised and frozen at -
80 °C. Western blotting was used to determine protein expression.  
Although no changes were observed in tumour growth between the different groups during 
the course of treatment, molecular events did occur. The reason being, that too much time 
has passed before the intervention started, and thus the tumours have already reached a 
large volume. The MKP-1 expression, as evaluated by western blotting, was significantly 
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inhibited in all treated groups when compared to the control (Figure 4.19). Treatment with 
sanguinarine in combination with doxorubicin induced the highest degree of apoptosis in 
these tumours (Figure 4.18). This was evident from a significant decrease in caspase 3 
expression in excised tumours. This echoed the results obtained from the in vitro study and 
can be supported by the fact that doxorubicin induces cell death in cancer cells (Gamen et al. 
2000). 
Following doxorubicin treatment LC3 II expression was not changed compared to control 
(Figure 4.20); however a decrease in p62 was evident indicating an increase in autophagy 
activity following doxorubicin treatment (Figure 4.21). This finding was expected as it had 
been proven that doxorubicin induced an autophagic response in cancer (Lambert et al. 
2008; Manov et al. 2011). Autophagy was also upregulated in these tumours as can be seen 
from the significant increase in LC3 II (Figure 4.20) expression and subsequent decrease in 
p62 (Figure 4.21) in mice treated with sanguinarine in combination with doxorubicin. The 
highest degree of autophagy was observed in the tumours treated with sanguinarine in 
combination with doxorubicin. This once again echoed the results obtained from the in vitro 
study for autophagy induction.  
5.3 Conclusions 
Collectively the results from both the in vitro and in vivo study indicate that sanguinarine 
therapy in conjunction with doxorubicin results in a higher degree of apoptosis when 
compared to other treatment groups and the highest level of autophagy was also observed 
for combined sanguinarine and doxorubicin therapy. This correlation indicate that the 
inhibition of MKP-1 together with doxorubicin treatment might act synergistically in inducing 
autophagy and apoptosis in MDA-MB231 and E0771 breast cancer cells. There is overlap 
between the two pathways and both doxorubicin and MKP-1 have been associated with 
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apoptosis, where doxorubicin induces apoptosis and MKP-1 expression inhibited apoptosis 
in cancer cells.  
Doxorubicin has also been shown to induce autophagy in cancer cells; however the effect of 
MKP-1 expression on autophagy in breast cancer cells is unknown. To establish if the 
observed correlation between autophagy and apoptosis has a causal link to MKP-1 
expression, autophagy and apoptosis were analysed during conditions of MKP-1 induction 
and MKP-1 inhibition. Results showed that by inducing MKP-1 with dexamethasone during 
doxorubicin treatment a significant decrease in apoptosis compared to doxorubicin 
treatment alone was observed. This finding could have far reaching implication in patients 
receiving glucocorticoid- and chemotherapy. It was also observed that when MKP-1 was 
inhibited with MKP-1 siRNA during doxorubicin treatment, it resulted in an increased degree 
of apoptosis compared to doxorubicin treatment alone. Combination therapy with 
sanguinarine and doxorubicin showed similar trends to combined MKP-1 siRNA and 
doxorubicin treatment, except that sanguinarine and doxorubicin together induced even 
greater levels of apoptosis.  
An increase in autophagy was observed under conditions of MKP-1 inhibition with 
sanguinarine and doxorubicin therapy compared to doxorubicin treatment alone. This 
indicates that the observed correlation between autophagy and apoptosis is linked to MKP-1 
expression as it was shown that by inhibiting MKP-1, the degree of autophagy and cell death 
increased.  
Levels of apoptosis and autophagy increased with the inhibition of MKP-1 in MDA-MB231 
cells and in E0771 cell tumours. Also, inhibiting MKP-1 with doxorubicin does act 
synergistically in inducing autophagy and apoptosis. These findings suggest that inhibiting 
MKP-1 with sanguinarine sensitized the MDA-MB231 cells and E0771 cell tumours to 
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doxorubicin-induced-apoptosis through a mechanism involving autophagy. This is an 
encouraging finding that could hopefully be used in future studies looking to overcome 
doxorubicin-resistance in breast cancer cells overexpressing MKP-1. 
5.4 Limitations and future studies 
It would be of great importance to further confirm our findings in an in vivo setting by 
increasing the sample size for better statistical power. Continuation of the research should 
investigate the mechanism involved in the up-regulation of autophagy in this scenario. JNK 
and p38 MAPK activation and expression was not quantified in this study.  
It would also be relevant to see if the effect that sanguinarine has, is blunted under 
conditions of autophagy inhibition. It would be of great benefit to investigate and identify 
the exact mechanism whereby MKP-1 inhibition results in autophagic induction in breast 
cancer cells. If there is indeed a direct link, it could be manipulated during the clinical setting 
to improve therapeutic options for breast cancer patients. 
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Protocol 1 – Cell Culture 
Breast carcinoma cells – MDA-MB231 cells 
Making up Growth medium 
Component Final percentage % 
DMEM 500 ml  
PenStrep 5.5 ml 1% 
Fetal Bovine Serum 10% 
Glutamine 20 ml  
 
Medium constituents must be thawed in a water bath at 37 °C and the volumes as specified above 
are added together under sterile conditions.  
 
Cracking a vile 
1. Remove a vial of MDA-MB231 cells from the liquid N2 tank and warm in the water bath at 37 °C 
until there is a small floating block of frozen cells. (be careful not to wet the lid of the cryovial)  
2. Remove cells from cryovile and grow in 5 ml growth medium in a T25 flask at 37 °C and 5% CO2. 
3. Wash cells in warm PBS and replace the medium every day until the cells reach ± 70% confluence 
4. When 70% confluence is reached cells are ready to be split. 
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Splitting and seeding of cells 
1. Split cells when a confluency of ~80% is reached. Confluency is determined by viewing cells under 
20x objective 
2. Warm growth medium, trypsin and PBS in the waterbath until a temperature of 37˚C is reached 
3. Decanted medium and rinse the monolayer once with PBS 
4. Decant PBS and add 4ml trypsin (T75) and place in the shaker incubator for ~ 4min. Check under 
the microscope to verify that cells are loose 
5. Now add double the amount of warm medium (8 ml in T75) and transfer to a falcon tube before 
centrifuging at 1500 rpm for 3 minutes. 
6. Decant the supernatant leaving just the pellet 
7. Add 5ml warm medium and gently re-suspend the pellet (use 1000 µl pipette)  
8. Count re-suspended cells using a haemocytometer and seed at following densities: 
A. 100 000 cells per well for 6 well plates 
B. 5000 cells per well for 96 well plates 
C. 300 000 cells per T75 flask 
After splitting and re-seeding, leave cells to plate for 48 hours before changing the medium in order 
to maintain healthy culture conditions.  Once 70% confluent, cells are ready to be split. Cell 
maintenance should remain consistent at all times 
 
Cell Freezing 
1. Use cells that are ~80% confluent 
2. Discard old medium using sterile pipette 
3. Rinse monolayer with warm sterile PBS  
4. Decant PBS and add 4 ml Trypsin (T75) and place in the shaker incubator for ~4min at 37˚C 
5. Now add double the amount of warm medium (8 ml in T75) and transfer to a falcon tube before 
centrifuging at 1500 rpm for 3 minutes. 
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6. Decant the supernatant leaving just the pellet 
7. Resuspended pellet in FCS at a concentration of 1-2 x 106 cells/ml 
8. Make up Freezing medium (10% DMSO) and add cells 
9. Transfer cells to -80˚C for 24h and then into liquid nitrogen 
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Protocol 2 – Reverse transfection 
For each petri dish to be transfected, prepare RNAi duplex-Lipofectamine RNAiMAX 
complexes in the following way:  
1. Prepare mastermix by diluting 20 pmol of duplex into 250 ul of transfection medium 
(medium containing no antibiotics or serum).  
2. Mix lipofectamine RNAiMAX gently and add 2 ul per 250 ul of mix.  
3. Resuspend and add 250 ul to each petri dish.  
4. Allow to incubate for 20 minutes.  
5. Split and dilute cells in growth medium (must contain no antibiotics) to have a final 
volume of 2 ml in each petri.  
6. Add 1.5 ml of diluted cell suspension to each well containing the RNAi duplex-
Lipofectamine RNAiMAX complexes.  
7. Mix gently  
8. Allow to incubate until cells are ready to treat (24-48 hours later).  
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Protocol 3 - Trypan Blue exclusion 
technique  
Trypan blue stock solution (0.4%) was prepared with PBS and stored in the dark at 4 °C  
Method 
1. Medium was removed from cells, washed with warm PBS and trypsinized as previously described 
(Protocol 1) 
2. Cell solution containing trypsin was neutralized using warm growth medium and centrifuged at 
1300-1500 rpm for 3 minutes 
3. The resulting pellet was resuspended in 200 µl warm PBS 
4. 50 µl suspension was added to 50 μl 0.4 % trypan blue solution and allowed to stand for 2-5 
minutes prior to counting 
5. 40 μl of the resuspended solution was placed into the haemocytometer and counted 
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Protocol 4 – Caspase-Glo® 3/7 assay  
Preparation of working reagent solution and storage:  
1. Mix the Caspase-Glo® 3/7 buffer reagent gently and allow to equilibrate at room 
temperature.  
2. Transfer the lyophilized substrate to the buffer and mix by swirling  
3. Store at -20°C. (Note that reconstituted reagent that is freeze thawed will display 
diminished signal over time – approximately 60% compared to freshly prepared reagent 
after 4 weeks according to the manufacturer. However, little reduction in signal intensity 
was noticed over longer time periods of freeze thawing in our experiments.)  
Assay protocol:  
1. Allow the working buffer reagent to equilibrate at room temperature for at least 30 
minutes.  
2. Remove plates containing cells from 37°C growing conditions to allow them to 
equilibrate at room temperature. (At least 10 minutes).  
3. Transfer 50 μl (1:1) of working reagent to each well containing cells.  
4. Mix plates on a shaker for 30 seconds.  
5. Incubate plates in the dark for 1 hour at constant room temperature. (Can incubate for 
up to 3 hours).  
6. Measure the luminescence in a luminometer. 
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Protocol 5 – Immunofluorescence 
microscopy 
LysoTracker™ and Hoechst staining 
1. Remove DMEM and wash cells with cold sterile PBS (3X) 
2. Add 1 μl LysoTracker™ per 2 ml of fresh medium 
3. Add 10mg/ml in a 1:200 dilution of Hoechst to the same medium 
4. Add this medium to the cells and allow to sit at room temperature for 5 min 
5. Do imaging 
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Protocol 6 – Flow cytometry 
Lysis of cells from monolayer 
1. Following completion of the treatment protocol, remove culture media and wash cells in 2 
ml PBS. 
2. Add 2 ml Trypsin/EDTA (0.25%) to each well and place on the cell shaker for 5 min or until 
the cells have detached from the surface of the well. 
3. Add 1 ml of appropriate culture medium to each well. 
4. Transfer each resulting cell suspension to a separate, sterile 15 ml falcon tube.  
5. Centrifuge at 1500 rpm for 3 min.  
6. Pour off the media-trypsin.  
Preparation of Samples for Analysis 
1. Re-suspend each cell pellet in 0.5 ml LysoTracker™ red (Invitrogen/Molecular Probes) 
working solution (final concentration of 100 nmol/L). 
2. Incubate the suspension for 15 min at 37ºC 
3. Gently re-suspend cell suspension directly before filtering through  into  FACS tube 
4. Analyse on the flow cytometer (BD FACSAria I) immediately  
5. Collect a minimum of 5000 events using 488 nm laser and 610LP, 616/23BP emission filters. 
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Protocol 7 - Protein extraction and 
centrifuging 
 
PBS: 
20 mM Tris HCL pH 7.4 
137 mM NaCl 
1 mM CaCl2 
1 mM MgCl2 
0.1 Sodium Orthovanadate 
RIPA Buffer: 
50 mM Tris-HCL  
1 mM EDTA  
1 mM phenylmethylsulfonyl fluoride (PMSF) 
1 mM benzamidine  
4 µg/ml SBTI-1  
1 µg/ml leupeptin  
1% NP40 
0.25% Na-deoxycholate. 
Protein extraction: 
1. Discard medium from wells and place immediately on ice. 
2. Rinse cell monolayer’s three times with PBS 
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3. Incubate for 5min in 250 ul RIPA  
4. Scrape cells from wells/flasks using a rubber policeman and transfer to 1.5 ml 
microcentrifuge tubes. 
 
 
Centrifuging and storage 
1. Centrifuge microcentrifuge tubes at 8000 rpm for 10min at 4ºC 
2. Label new microcentrifuge tubes and place on ice  
3. Decant into new correctly labelled microcentrifuge tubes 
4. Store tubes at -80ºC overnight 
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Protocol 8 – Western blotting 
 
Bradford Reagent: (5x concentrated) 
Dilute 500 mg of Coomasie Brilliant Blue G in 250 ml 95% ethanol 
Add 500 ml of Phosphoric acid and mix thoroughly  
Make up to 1 L with dH2O 
Filter and store at 4ºC 
 
Bradford Working Solution 
Dilute stock in 1:5 ratio with dH2O 
Filter using 2 filter papers at the same time 
Solution should be a light brown colour 
 
Bradford quantification 
1. Thaw a 1 mg/ml BSA stock solution 
2. Thaw protein samples if in -80°C freezer – Keep on ice at all times 
3. Make up a working solution of 100 µl BSA: 400 µl dH2O. Vortex mixture 
4. Mark 7 eppendorf tubes for the standards as well as tubes for the samples to be 
tested 
5. Now add BSA and water to marked Eppendorf tubes as follows: 
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Blank 0 µl BSA 100 µl dH2O 
2 µg protein 10 µl BSA 90 µl dH2O 
4 µg protein 20 µl BSA 80 µl dH2O 
8 µg protein 40 µl BSA 60 µl dH2O 
12µg protein 60 µl BSA 40 µl dH2O 
16 µg protein 80 µl BSA 20 µl dH2O 
20 µg protein 100 µl BSA 0 µl dH2O 
Each sample 0 µl BSA 95 µl H2O 5 µl of sample protein 
 
6. Vortex all tubes briefly 
7. Now add 900 µl of Bradford reagent to each Eppendorf tube. Vortex again. 
8. Incubate at room temperature 
9. Read absorbencies, twice each, at 595 nm. 
10. Make use of excel to draw a linear plot of absorbencies vs protein concentration and then 
calculate the amount of each sample to be added to aliquots. 
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SDS-PAGE and western blotting 
1. Clean pairs of large and small glass plates with methanol and a paper towel. 
2. Place the small glass plate onto the large plate and slide these into the green assembly.  
3. Tighten the assembly by pushing the green clips outward. 
4. Place the assembly on the rubber, pushing down gently. 
5. Get two small beakers, two Pasteur pipettes and a small stirring bar. 
6. Fill one beaker with H2O and get isobutanol ready. 
7. Separating gel recipe for 10% 1 mm gels: 
4 ml  dH2O 
2.5 ml  1.5M Tris-HCL pH 8.8 
0.1 ml  10% SDS (stock) 
0.1 ml  10% APS (0.1 g/ml) 
3.3 ml  Acrylamide 40% 
4 µl  Temed 
8. Add everything except for the APS and Temed and let the mixture stand for a few minutes so 
to allow it to degas. 
9. Add the APS first and stir briefly (~30 seconds) 
10. Add Temed and mix the solution momentarily 
11. Quickly pour the mixture between the glass plates using a Pasteur pipette leaving enough 
space for the stacking gel. 
12. Add a layer of isobutanol using a fresh Pasteur pipette. 
13. Allow to set for 1 hour. Prepare running buffer and TBS-T in 1:10 dilutions. 
14. After 45 minutes has passed begin to prepare the stacking gel (4% recipe): 
15. Once the gels are set (after 1 hour), wash off the isobutanol and make sure that the plates 
are dry. 
16. Add Temed to the stacking solution, mix quickly and add stack between the plates. 
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17. Gently push combs (of the correct width) into the stacking gel. 
18. Leave to set for 30 minutes 
19. At this stage, retrieve the standard marker from the freezer and allow it to warm to room 
temperature 
20. Switch on the heating block (it must reach a temperature of 95 °C). 
21. Retrieve prepared samples for the -80 °C freezer and allow them to thaw. 
22. Ready the electrophoresis apparatus for use. 
23. Once thawed, vortex each sample briefly before denaturing in the heating block for 5 
minutes. 
24. In the meantime, carefully remove the combs and wash the gels gently with H2O being 
careful not to damage the wells. 
25. Vortex each sample briefly before centrifuging by pulsing for a few seconds. 
26. Take the gel plates out of the assembly stand and place them into the U-shaped adaptor 
cassette. The small plates must be facing inwards. 
27. Place the U-shaped adaptor into the loading system and push the latches closed, away from 
you. 
28. Carefully pour prepared running buffer into the middle compartment between the gel plates, 
allowing the buffer to flow over in the wells. 
29. Add 7.5µl of molecular weight marker into the first well on the left of each gel. Remember 
that the left of the far gel will be on your right hand side. 
30. Add your samples into each well using a micropipette and loading tips. 
31. Place the system into the outer running chamber, and add running buffer to approximately 
1cm below the wells. 
32. Place the green lid onto the system making sure to attach the correct electrodes (red to red 
and black to black) 
33. Perform an initial ten minute run at 100 V (constant) and 400 mA. 
34. Thereafter, perform a longer run (usually ~50 minutes) at 200 V (constant) 
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35. Turn off the power and disconnect the electrodes before removing the gel plates from the 
system. Proteins will slowly dissolve form the gel, so do not let the gels stand at this point. 
Move directly onto the transfer step. 
36. Electrotransfer can now be performed on the semi-dry apparatus. 
37. Cut 8 Whatman 3mm filter papers and one PVDF membrane per gel. 
38. For every membrane soak three papers in anode buffer 1 (0.3 M Tris-base, pH 10.4, 20% 
methanol) 
39. Soak one paper in anode buffer 2 ( 25mM Tris-base, pH 10.4, 2% methanol) 
40. Place these papers – first those from anode buffer 1 then from anode buffer 2 – onto the 
anode plate. Roll them flat with a test tube to remove air bubbles. 
41. Soak one PVDF membrane in methanol for 15 seconds and then rinse with water before 
soaking it in anode buffer 2. Place the membrane onto the anode buffer 2 papers already on 
the anode plate. Role again to remove any bubbles. 
42. Carefully remove gels from their respective plates – make sure that the gels do not tear in 
the process – and place them onto the membranes. Role with a wet tube to remove any 
bubbles that may have formed. 
43. Soak four papers in cathode buffer (25 mM Tris-base, 40 mM ε-aminohexanoic acid, pH 9.4, 
20% methanol), and place these onto the gel. 
44. Close the system and run at limit 0.5A and 15V for one hour. 
45. Wash the membranes in copious amounts of prepared TBS-Tween (allow foam to develop. 
Wash three times for five minutes. 
46. Block the membranes in non-fat milk (5 g/100ml TBS-T) for two hours on the belly dancer. 
47. Make up the primary antibody (5 µl in 5 ml TBS-T).  
48. Mix in the walk in freezer overnight. 
49. Wash membranes in TBS-T with agitation. Three times for five minutes. 
50. Place the membranes in the HRP-conjugated secondary antibody (1.25 µl in 5 ml TBS-T). 
Incubate with agitation for one hour. 
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51. To expose, use the ECL detection kit. 
52. Add 500 µl of each of the ECL cocktail kit to a foil covered falcon tube and vortex briefly. 
53. Cover the area of the membrane known to have the bands that you are looking for, for one 
minute. 
54. Expose membranes in the dark room. 
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Protocol 9 - Cancer cell injection 
Adapted from Ewans et al. 2006 (Doxorubicin plus Interleukin-2 Chemoimmunotherapy against 
Breast Cancer in Mice). 
1. Culture E0771 cells until 80% confluent. 
2. Digest cultured E0771 cells using trypsin (0.05% trypsin-EDTA) for 5 minutes at 37°C. 
3. Centrifuge at 1500 rpm for 3 minutes. 
4. Wash cells once with sterile PBS. 
5. Count cells and dilute with Hanks Balanced Salt solution to a concentration of 1250 cells/µl 
(2.5x105 cells in 200 µl)  
6. Inject the cell suspension s.c. in the lower abdomen of each mouse, in or near the no. 4 
mammary fat pad (Day 0) 
 
MICE Subcutaneous injection:  
Adapted from Guidelines for Handling, Restraint, Injections and Blood Collection from Small 
Laboratory animals (http://campusvet.wsu.edu/infofac/handling.htm). 
SC injections can be administered easily to mice. The needle is inserted between the folds of 
skin into the base of the triangle that is formed when traction is applied to the skin overlying 
the animal's scruff. The syringe's plunger should be retracted to verify that a vacuum is 
created and no blood or tissue fluid can be aspirated. Subsequently, the plunger is 
depressed releasing the material. In general no greater than 1 ml should be injected per SC 
injection site in adult mice (> 25 grams). Several sites over the animal's back should be used 
if larger volumes must be administered. In general, needles should be 0.5 - 1 long and 23 ga 
or larger gauge.  
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Reagents 
 
X1 Phosphate Buffer Saline (PBS)-2L 
Dissolve the following in 1 L of water 
 16 g NaCl 
 0.4 g KCl 
 2.88 g Na2HPO4 (di Sodium hydrogen phosphate) 
 0.48 g KH2PO4 (potassium dihydrogen phosphate) 
 Adjust pH to 7.4, fill up to the 2 L mark with distilled water and sterilize by autoclaving 
 
Trypan Blue dye 
 Weigh out 40 g trypan blue dye and dissolve this in 100 ml PBS 
 Store away at 4 °C 
 
BSA (Bovine serum albumin 1mg/ml) 
 For 1 ml BSA, weight out 1 mg BSA and add 1000 μl distilled water. 
 For use during Western blotting, this BSA needs to be diluted. Pipette 100 μl from 1 mg/ml BSA 
in new eppendorf tube and add 400 μl distilled water 
 Mix well 
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Bradford Reagent (1L) 
 Weigh out 500 mg Coomassie Brilliant Blue G and add it to 25 ml 95% ethanol 
 Add 500 ml phosphoric acid and mix well 
 Fill up to 1 L with distilled water and store at 4 °C 
 Filter twice and make 1:5 dilution for Western blotting 
 
3X Sample buffer 
 Measure 33.3 ml stacking Tris (0.5 M) and place in a beaker 
 Weight out 8.8 g SDS and 20 g glycerol and place in the beaker 
 Add a pinch of Bromo-phenol blue to the mixture 
 Add and make up to 75.47 ml with distilled water 
 
1.5 M Tris pH 8.8 (500ml) 
 Weigh out 68.1 g Tris (1.124 M) and 1.5 g SDS (0.3 %) and place in a beaker. 
 Add 400 ml distilled water, stir and then adjust pH using HCL 
 Add 100 ml distilled water to make the final volume to 500 ml 
 
1.5 M Tris pH 6.8 (500ml) 
 Weigh out 30.3 g Tris (0.5 M) and 2 g SDS (0.4 %) and place in a beaker. 
 Add 400 ml distilled water, stir and then adjust pH using HCL 
 Add 100 ml distilled water to make the final volume to 500 ml 
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10% Sodium dodecyl sulphate (SDS 500ml) 
 Weigh out 50 g SDS and dissolve it in 500 ml distilled water using a volumetric flask 
 
10% Ammonium persulphate (1000 μl) 
 Weigh out 0.1 g APS into an eppendorf tube and add 1000 μl distilled water 
 
Running buffer (1L) 
 Weigh out 3.03 g Tris, 1.44 g Glycine and 1 g SDS into a 1 L beaker. Add 500 ml distilled water and 
stir until dissolved. 
 Fill up to 1 L with distilled water 
 
10X TBS (5L) 
 Weigh out 121 g Tris and 80 g NaCl into a 5 L beaker. Add 2.5 L distilled water and stir until 
dissolved. 
 Adjust pH to 7.6 using HCl and then fill up to 5 L with distilled water 
 For use in Western blotting, take a 1 L measuring cylinder and add 100 ml 10X TBS and dilute 
with 900 ml distilled water 
 To make TBST, add 1 ml tween to 1 L diluted solution of TBS 
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Milk blocking solution (100ml) 
 Weigh out 5 g non-fat dry instant milk powder into a beaker. Add 100 ml TBST and mix well 
 
Primary (1°) antibody 
 Pipette 5 μl 1° antibody and 5 ml TBST in a 50 ml falcon tube. This concentration is suitable for 
most 1° antibodies but others require a higher concentration 
 
Secondary (2º) antibody 
 Pipette  2.5 µl 2° antibody and 5 ml TBS-Tween20 in a 50ml falcon tube 
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